



Smoking and healthcare and welfare costs. A Cohort Study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001678
Article Type:	Research
Date Submitted by the Author:	20-Jun-2012
Complete List of Authors:	Tiihonen, Jari; University of Eastern Finland, Dept of Forensic Psychiatry; Karolinska Institutet, Dept of Clinical Neuroscience Ronkainen, Kimmo; University of Eastern Finland, Institute of Public Health and Clinical Nutrition Kangasharju, Aki; Government Institute for Economic Research, Kauhanen, Jussi; University of Eastern Finland, Institute of Public Health and Clinical Nutrition
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Epidemiology, Health economics
Keywords:	EPIDEMIOLOGY, HEALTH ECONOMICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

Word count for text only: 2716 words

Smoking and Healthcare and Welfare Costs. A Cohort Study.

Jari Tiihonen Professor and Chairman^{1,2,3}, Kimmo Ronkainen IT specialist⁴, Aki Kangasharju Director General⁵, Jussi Kauhanen Professor and Chairman⁴

Author Affiliations: ¹Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; ²National Institute for Health and Welfare, Helsinki, Finland; ³Departments of Psychiatry and Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital and Kuopio University Hospital, Kuopio, Finland; ⁴Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; ⁵Government Institute for Economic Research, Helsinki, Finland

Correspondence to: Prof. Jari Tiihonen, MD, PhD, Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Niuvankuja 65, FI-70240 Kuopio, Finland, tel. +358 17 203 202; fax: +358 17 203 494; jari.tiihonen@niuva.fi

Keywords: smoking; healthcare; costs; mortality

Submitted to BMJ Open, June 20, 2012

Abstract

Objective: To study the net economic effect of smoking on society.

Design, Setting, and Patients: We studied mortality, paid income and tobacco taxes, and the cumulative costs due to pensions and medical care among both tobacco smoking and non-smoking individuals in a 27-year prospective cohort study of 1,976 men from Eastern Finland. These individuals were 54–60 years old at the beginning of the follow-up.

Main Outcome Measures: The net contribution of smoking vs. non-smoking individuals to public finance balance (euros).

Results: Smoking was associated with a greater mean annual health care cost of €1,600 per living individual during follow-up. However, due to a shorter life span of 8.6 years, smokers' mean total healthcare costs during the entire study period were actually €4,700 lower than for non-smokers. For the same reason, each smoker missed 7.3 years (€126,850) of pension. Overall, smokers' average net contribution to the public finance balance was €133,800 greater per individual compared with non-smokers. However, if each lost quality adjusted life year is considered to be worth €22,200, the net effect is reversed to be €70,200 per individual in favour of non-smoking.

Conclusion: Smoking was associated with a moderate decrease in health care costs, and a marked decrease in pension costs due to increased mortality. However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

Introduction

Smoking is the single most important preventable cause of premature death in industrialized countries¹, and tobacco taxation is still the most cost-effective method for decreasing the prevalence of smoking. Increases in tobacco taxes have encouraged 9 to 17% of smokers to quit^{2,3}, and in the long run the main effect of taxation is a reduction in the incidence of new young smokers.⁴ Early smoking cessation increases lifespan by about 9-10 years,⁵ and if the smoking rate diminished by 10 percentage points, life expectancy would increase by about one year. It has been estimated that a 10% increase in the price of smoked tobacco will result in about a 5% decrease in cigarette consumption,⁴ yet tobacco taxes are still low in many countries. Thus, it would be interesting to know why so many governments in the world continue to increase spending on health care costs, while a substantial savings and advances in life expectancy are readily available by administratively increasing tobacco taxes? There are two plausible explanations: the governments do not know about the correlation between increasing tobacco taxes on increasing life expectancy, or they realize this effect, but do not want to increase the life expectancy.

The net effect of smoking on healthcare costs has been investigated in several studies.⁶⁻¹⁶ Some modelling studies have suggested that while smokers suffer more from many kinds of diseases, non-smokers incur more healthcare costs because they live longer,^{6,7,8,11,12} yet others have reached the opposite conclusion.^{9,10,13-16} Only two of these studies have included both pension and insurance costs,^{7,12} and only one study has included paid tobacco taxes.¹² In 2001, Philip Morris provided a report to the Government of the Czech Republic, which indicated that the effect of smoking on the public finance balance in the Czech Republic in 1999 was positive and estimated to be 5,815 million korunas (about 150 million USD).¹² Although this report generated outraged reactions worldwide, Milos Zeman, the Czech prime minister stated "As a smoker, I support the state budget, because in the Czech Republic, we pay tax on tobacco. Also, smokers die sooner, and the state does not need to look after them in their old age".^{17,18} To our knowledge, the Philip Morris report is the only published study thus far on the overall effect of smoking on the balance of public finance. This report was based on many assumptions that were obtained through theoretical modelling, and it did not give any monetary value for life years lost because of

1
2
3 smoking, and it was claimed to have underestimated the costs of medical care for people
4 suffering from smoking related diseases.¹⁹ As shown by van Baal et al., slightly different
5 models can give markedly different results on the net effect of smoking, depending what
6 assumptions are used²⁰. In any case, sophisticated incidence-based datasets are
7 ultimately required to establish the true health care costs incurred by smoking.²¹ Because
8 no results have been obtained from empirical data based on mortality, morbidity, pension
9 and health care costs, the net economic impact of smoking on society has remained
10 unclear. The aim of this study was to investigate this net economic effect by using data
11 from a prospective 27-year follow-up of a cohort of 1,976 Finnish middle-aged men.
12
13
14
15
16
17
18
19

20 Methods

21 Study population

22
23
24
25
26 The subjects of the Kuopio Ischemic Heart Disease study (KIHD) were obtained from a
27 randomly selected sample of 3,433 men, aged 42 to 60 years, who resided in the town of
28 Kuopio or its surrounding rural communities. Of those invited, 2,682 (83 %) participated in
29 the study. Of these, individuals from 54 to 60 years with complete data for smoking,
30 income, healthcare costs, retirement, and mortality (n=1,976 men) were included in the
31 final analyses. The baseline examinations were conducted between March 1984 and
32 December 1989.²² The mean follow-up time was 24.2 years (range 21.1±26.8 years). The
33 KIHD study was approved by the Research Ethics Committee of the University of Kuopio,
34 in Kuopio, Finland. Each participant gave written informed consent. The end of follow-up
35 period was December 31, 2010.
36
37
38
39
40
41
42
43
44

45 A subject was defined as a smoker if he had ever smoked on a regular basis, and had
46 smoked cigarettes, cigars, or a pipe within the past 30 days. The lifelong exposure to
47 smoking ("cigarette pack-years") was estimated as the product of years smoked and the
48 number of tobacco products smoked daily at the time of examination. "Years smoked"
49 were defined as the sum of years of smoking regardless of when smoking had started,
50 whether the subject had stopped smoking, or whether it had occurred continuously or
51 during several periods. Data on mortality was obtained from Statistics Finland, and data on
52 healthcare costs from the Finnish Institute for Health and Welfare (THL). The health care
53
54
55
56
57
58
59
60

1
2
3 costs did not include visits to general practitioners, home nursing, or medication and dental
4 care costs in outpatient care, which have been estimated to be about 20–30% of total
5 health care costs in this age group in Finland.²³ The amount of paid tobacco taxes was
6 estimated on the basis of cigarette pack-years,²⁴ and the amount of paid income taxes was
7 estimated by using the income tax rate of year 1987. The amount of occupational
8 productivity and income taxes lost was calculated as the difference of age at retirement
9 (relative to the retirement age of matched non-smokers) multiplied by the annual income
10 and income tax of each smoker. “Income taxes paid” also included obligatory pension and
11 healthcare insurance fees. All monetary values were expressed as Euros (€) and
12 converted to the level of year 2009.

13
14
15
16
17
18
19
20
21 In the United Kingdom, the monetary value of one quality adjusted life year (QALY) has
22 been estimated to be 20,000–30,000 Pounds for an individual having perfect health.²⁵ In
23 the present study, we used a value of 30,000 Euros (about 25,100 Pounds in February
24 2012). In a recent large study on the effect of smoking on life expectancy, the quality-of-life
25 score among former smokers with a BMI of 25–30, who were older than 65-years was
26 estimated to be 0.71–0.77.²⁶ Therefore, we used a quality-of-life score of 0.74 for smokers
27 in the present study, thus equalling to 0.74 x 30,000 Euros = 22,200 Euros for each life
28 year lost due to smoking among former smokers aged over 65 years (deceased smokers
29 who would be over 65 if they had lived).

30 31 32 33 34 35 36 37 38 **Statistical analysis**

39
40
41 Differences in baseline characteristics and costs were examined using the Student's t-test.
42 Descriptive data are presented as means and percentages. A p-value of less than 0.05
43 was considered statistically significant. These statistical analyses were performed using
44 SPSS 17.0 for Windows. Life expectancy for those individuals still alive on 31st December
45 2009 was calculated by using life expectancy from the Life Table provided by Statistics
46 Finland.²⁷

Results

The crude mortality rates were 351/493 (71.2%) among smokers, and 553/1483 (37.3%) among non-smokers, and the cause-specific mortality in each group is shown in Table 1. The observed age at death was 67.8 years for smokers, and 71.4 years for non-smokers. The predicted mean age at death was 72.1 for smokers and 80.7 years for non-smokers, indicating 8.6 years difference between two groups. When the effect of birth year on life expectancy was taken into account, the amount of life years lost due to smoking was 9.2 years. The demographic variables and smoking-related outcomes are shown in Table 2. Smokers had substantially lower mean BMI and educational level. Smokers also had a slightly lower mean systolic blood pressure and a slightly higher mean LDL cholesterol level. Smoking was associated with a moderate decrease in productive occupational career, income taxes paid, and hospital care costs, and showed a marked decrease in pension costs. The net effect of smoking on public finance was plus € 133,800 for these smokers during the follow-up when life years lost were not included, and minus € 70,200 when a monetary value for life years lost was included in the calculation.

Figure 1 demonstrates the average annual healthcare costs as a function of age among those individuals still alive, and Figure 2 shows the corresponding results when all individuals (also deceased) are included. The higher mortality results into lower annual costs among smokers after 72 years from birth.

Discussion

Hospital care costs were 1,600 Euros greater per person year for living individuals among the smokers during the follow-up, but due to a 8.6 year shorter life span, the total costs per individual were 4,700 Euros lower among smokers than non-smokers during the entire study period. This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective empirical data.

Smoking resulted in a moderate decrease in the productive occupational career and income taxes and pension fees paid, a moderate decrease in health care costs, and a

1
2
3 marked decrease in the pension costs. The costs of smoking to society have been
4 modelled by using estimates on increased mortality and morbidity.⁶⁻¹⁶ However, none of
5 these modelling studies investigated the overall net economic effect of smoking on public
6 finance balance by using empirical data from individuals, or by taking into account all of
7 the following factors; lifetime productivity or income taxes and pension fees paid, pension
8 costs, and a monetary value of life years lost. Combined, these factors make considerable
9 contribution to the overall net effect than merely health care costs. If the potential increase
10 in quality adjusted life years is taken into account, our results suggest that the life long net
11 beneficial economic effect of early smoking cessation is more than € 70,000 per individual.
12 Our results also indicate that reducing the rate of smoking has a huge beneficial economic
13 effect on society, mainly due to increased life span and continued pension costs. In
14 Finland, the National Institute for Health and Welfare aims to make Finland free of smoking
15 by the year 2040. Since there are currently about 900,000 smokers in Finland, the average
16 net effect of € 134,000 per individual on public finance balance (without taking into account
17 the monetary value of life years lost) would correspond during the next decades to about
18 120 billion Euros total increase in costs (over 2.5-fold to annual state budget). However,
19 this nominal deficit would be massively outweighed by about 2 years increase in life
20 expectancy of the whole nation.
21
22
23
24
25
26
27
28
29
30
31
32
33

34 The only other study that has considered the effect of lost productivity and paid tobacco
35 taxes was by Arthur Little for Philip Morris in 2001.¹² Our overall results on the net
36 economic effect of smoking on public finance balance are contrary to the Philip Morris
37 report. A major reason for this difference is that Little did not consider the inherent value of
38 the quality adjusted life years lost. In other words, if we used an estimate of 0 Euros for
39 each lost year of human life, then the positive economic effect of smoking in our study
40 would have been even larger than the effect estimated by Little. However, when
41 considering the implications of these results, the major question is whether or not humans
42 are to be valued as commodities, like domesticated animals, or does human life maintain
43 an inherent value even when the individual is not longer economically productive, as in
44 retirement? In the field of health care, it is generally assumed that all human life – even
45 that of the old and disabled – is precious and has value. This view is also currently
46 accepted by national authorities throughout most of the modern world. Already in 1999,
47 387 billion USD was used in the U.S. for medical treatment and care of people older than
48 65 years.²⁸ Nowadays it is generally agreed that the monetary value of one additional life
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 year of a healthy human being is about 20,000-30,000 British Pounds when additional
4 costs of medical care are considered.²⁵ One may ask why societies continue to invest
5 even larger amounts of money and other social resources to achieve a longer mean life
6 span for citizens, while a more drastic increase could be achieved administratively, without
7 any further costs, by substantially raising tobacco taxes and otherwise restricting access to
8 smoking? There are two likely answers: either governmental authorities have not realized
9 this fact, or they have realized it, but do not want to increase life expectancy due to a
10 subsequent increase in both health care and pension costs.
11
12
13
14
15
16
17

18 While denying access to medical care for older people, in order to prevent a deficit in
19 national economy, would not be possible because of common ethical concerns and public
20 opinion, preventing a decrease in smoking rates essentially has the same effect, and is
21 apparently more accepted by many societies. If this is the case, it would also explain the
22 reluctance of governments to regulate the eating and other consumption habits of that
23 negatively affect the general population by, for example, increasing the value added tax
24 (VAT) on food products that are high in sugar and saturated fats, and decreasing VAT on
25 fruits and vegetables, for example. The Czech prime minister stated in 2001 that smoking
26 is beneficial for the state, because smokers die sooner.^{17,18} Such comments have not been
27 echoed by other state leaders since, however it is plausible that this view still influences
28 tobacco policies in many modern countries. Therefore, governments should be transparent
29 concerning which kind of knowledge their tobacco and food taxation policy is based on.
30
31
32
33
34
35
36
37
38

39 The strength of this study is based on empirical data that was gathered from a 27-year
40 prospective study. Thus, no assumptions on healthcare, pension costs or discount
41 percentages of future costs were needed. One shortcoming is that this study did not
42 include females, and it did not include visits to general practitioners, home nursing, or
43 medication and dental care costs in outpatient care, which contribute to about 20–30% of
44 the total health care costs among elderly and middle aged people in Finland.²³ In a
45 previous 19-year follow-up study, it was observed that while the overall healthcare costs
46 were higher among smokers aged 25–59 years, the costs of medication in outpatient care
47 did not differ between smokers and non-smokers.²⁹ Thus it can be further estimated that
48 the total health care costs might have been at the most about 6,000 to 7,000 Euros higher
49 per individual among non-smokers when compared with smokers, instead of our modest
50 estimate of about 5,000 Euros per individual. However, the magnitude of this difference
51
52
53
54
55
56
57
58
59
60

1
2
3 (€ 1,000–2,000) is less than 2% of the pension costs, and does not have any substantial
4 effect on these results. We also did not include the costs of fires or littering related to
5 smoking, as this information was not available, yet the combined contribution of these
6 factors is probably less than 1% of the total costs.¹² Since only 17% of the initiated
7 subjects refused to participate, the generalisability of results can be considered quite
8 sufficient.
9
10
11
12

13
14 It was presumed that smokers' lower education level and lower income level were not
15 caused by smoking, and that differences in these characteristics were associated with
16 smoking due to the fact that less educated individuals are more likely to start smoking than
17 individuals with higher educational level. Therefore, it was assumed that smoking
18 cessation would not substantially increase education level or income. It can be estimated
19 that during a productive career of about 35 years, with an annual difference of € 2,970 in
20 paid income taxes, smokers in our study have paid an average about 100,000 Euros less
21 income taxes than non-smokers. If it were assumed that early smoking cessation would
22 change these variables to the same levels as with non-smokers, the net difference
23 between smokers vs. non-smokers would shift from € 134,000 to about € 30,000 in favour
24 of smoking, if the value of life years lost are not included, and from € 70,000 to about €
25 170,000 in favour of non-smoking if the value of life years lost are included in the analysis.
26 Either way, the principal conclusions on the net costs would remain the same. It is
27 questionable if the tobacco taxes should be considered as beneficial increases in income
28 to the state. For example, if an individual would not have been smoking, then he/she
29 probably would have consumed more goods in the extra years of life and thus paid more
30 taxes for those goods instead of the taxes paid for cigarettes. Overall, the estimate of a €
31 70,000 beneficial effect of early smoking cessation per individual is probably an
32 underestimate.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

1) Article Focus

- No results have been obtained from empirical data based on mortality, morbidity, pension and health care costs and, therefore, the net economic impact of smoking on society has remained unclear.

2) Key Messages

- Both the healthcare and pension costs are lower for smokers than non-smokers, the overall difference being more than 100,000 euros per individual.
- However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

3) Strengths and Limitations

- This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective empirical data.
- Only males were included in study.

Funding/Support: This project was funded by the Ministry of Health and Social Affairs (Finland), the National Institute for Health and Welfare (THL) and the Academy of Finland. The funders were not involved in the conduct of the study, or in the collection, management, analysis or interpretation of the data.

Competing Interest: All authors have completed the Unified Competing Interest form at www.icmj.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: Dr Tiihonen is a member of advisory board of AstraZeneca and Janssen-Cilag, and he reports serving as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, and lecture fees from Janssen-Cilag, Bristol Myers-Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, Novartis, and Astra Zeneca. No further disclosures were reported.

Contributors: JT, KR and JK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JT wrote the first draft of the manuscript and all other authors read and had input in the final version of the paper. JT did study concept and design, KR and JK collected data, KR did statistical analysis and KR produced figures. JT is the guarantor.

Ethical approval: The KIHD study was approved by the Research Ethics Committee of the University of Kuopio, in Kuopio, Finland.

Data sharing: No additional data available.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).

References

- 1 Schroeder SA, Warner KE. Don't forget tobacco. *N Engl J Med* 2010;363:201-4.
- 2 Dunlop SM, Cotter TF, Perez DA. Impact of the 2010 tobacco tax increase in Australia on short-term smoking cessation: a continuous tracking survey. *Med J Aust* 2011;195:469-72.
- 3 Choi TC, Toomey TL, Chen V, *et al.* Awareness and reported consequences of a cigarette tax increase among older adolescents and young adults. *Am J Health Promot* 2011;25:379-86.
- 4 Gallet CA, List JA. Cigarette demand: a meta-analysis of elasticities. *Health Economics* 2003;12:821-35.
- 5 Doll R, Peto R, Boreham J, *et al.* Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
- 6 Leu RE, Schaub T. Does smoking increase medical care expenditure? *Soc Sci Med* 1983;17:1907-14.
- 7 Manning WG, Keeler EB, Newhouse JP, *et al.* The taxes of sin. Do smokers and drinkers pay their way? *JAMA* 1989;261:1604-9.
- 8 Lippiatt BC. Measuring medical cost and life expectancy impacts of changes in cigarette sales. *Prev Med* 1990;19:515-32.
- 9 MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco use. *N Engl J Med* 1994;330:975-80.
- 10 Smoking-related deaths and financial costs: estimates for 1990. Rev. ed. Washington, DC: Office of Technology Assessment, 1993.
- 11 Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. *N Engl J Med* 1997;337:1052-7.
- 12 Arthur D. Little International, Inc. Philip Morris funded study of smoking in the Czech Republic stating that the Czech government had a net gain of \$147.1 million from smoking. <http://www.mindfully.org/Industry/Philip-Morris-Czech-Study.htm>. Accessed November 21, 2011.
- 13 Yang L, Sung HY, Mao Z, *et al.* Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. *Tob Control* 2011;20:266-72.

- 1
2
3 14 Callum C, Boyle S, Sandford A. Estimating the cost of smoking to the NHS in
4 England and the impact of declining prevalence. *Health Econ Policy Law* 2011;6:489-
5 508.
6
7
8 15 Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. *Soc*
9 *Sci Med* 1999;48:375-91.
10
11 16 Miller LS, Max W, Sung HY, *et al.* Evaluation of the economic impact of California's
12 Tobacco Control Program: a dynamic model approach. *Tob Control* 2010;19(Suppl
13 1):i68-i76.
14
15
16 17 L'Organisation mondiale de la Santé. Guide pour la mise en place de l'action
17 antitabac. 2006, p. 21.
18
19 18 Holley David (August 05, 2001): "Philip Morris Angers Czechs With Tobacco Toll
20 Report – Los Angeles Times" ([http://articles.latimes.com/2001/aug/05/news/mn-](http://articles.latimes.com/2001/aug/05/news/mn-30831)
21 30831). Los Angeles Times. Accessed December 12, 2011.
22
23 19 <http://www.tobacco.org/news/70612.html>. Accessed December 23, 2011.
24
25 20 van Baal PH, Feenstra TL, Polder JJ, *et al.* Economic evaluation and the
26 postponement of health care costs. *Health Econ* 2011;20:432-45.
27
28 21 Heaney D. The health care costs of smoking. *N Engl J Med* 1998;338:471; author
29 reply 472.
30
31 22 Lakka TA, Venäläinen JM, Rauramaa R, *et al.* Relation of leisure-time physical
32 activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men.
33 *N Engl J Med* 1994;330:1549-54.
34
35 23 Kuntaliitto. Suurten kaupunkien terveydenhuollon kustannukset vuonna 2010.
36 Helsinki: Suomen kuntaliitto, 2011.
37
38 24 Official Statistics of Finland. Tobacco Statistics 2009. Helsinki: Statistics Finland,
39 2010.
40
41 25 National Institute for Health and Clinical Excellence. Measuring effectiveness and
42 cost effectiveness: the QALY.
43 [http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivene](http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp)
44 [sstheqaly.jsp](http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp). Accessed December 12, 2011.
45
46 26 Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on
47 U.S. life expectancy. *N Engl J Med* 2009;361:2252-60.
48
49 27 Statistics Finland. Life Table 2007/Life expectancy of men, by age. Statistics Finland.
50 <http://www.staft.fi/til/kuol/tau.html>. Accessed February 9, 2012.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28 Keehan SP, Lazenby HC, Zezza MA, et al. Age Estimates in the National Health
4 Accounts. *Health Care Financing Review* 2004 Dec. 2; 1(1); Web Exclusive.
5
6 29 Kiiskinen U, Vartiainen E, Puska P, *et al.* Smoking-related costs among 25 to 59
7 year-old males in a 19-year individual follow-up. *Eur J Publ Health* 2002;12:145-51.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).

For peer review only

Table 1. Cause-specific mortality among smokers and non-smokers.

Cause of death	Non-smokers (%)	Smokers (%)
Cardiovascular disease	267 (48%)	166 (47%)
Cancer (all)	146 (26%)	102 (29%)
Lung cancer	15 (3%)	47 (13%)
Respiratory disease	13 (2%)	20 (6%)
External causes of death	56 (10%)	28 (8%)
Other	71 (13%)	35 (10%)
Total	553 (100%)	351 (100%)


A total of 553 (37.3%) non-smokers and 351 (71.2%) smokers had died during the follow-up. Percentages indicate the proportions for cause of death from all deaths in each group. Cancer deaths include lung cancer deaths.

Table 2. Smoking-related outcomes.

	Non-smokers N=1483		Smokers N=493		Difference of means	p-value
	Mean	S.D.	Mean	S.D.		
Age at baseline, years	55.72	2.50	55.54	2.38	-0.2	0.17
Body mass index (BMI)	27.29	3.51	26.01	3.81	-1.3	< 0.001
Mean systolic blood pressure (mm Hg)	135.93	17.43	133.43	18.18	-2.5	0.007
LDL-cholesterol (mmol/l)	4.07	1.01	4.21	1.09	0.1	0.013
Years of education	8.19	3.32	7.52	2.74	-0.7	< 0.001
Age at death, years	80.71	8.40	72.13	8.89	-8.6	< 0.001
Life years lost due to smoking	0	0	9.19	8.15	9.2	< 0.001
Age at retirement, years	56.60	5.89	55.35	6.23	-1.3	< 0.001
Years of receiving pension	23.69	9.11	16.42	9.39	-7.3	< 0.001
Number of hospitalizations	10.74	12.34	10.84	10.89	0.1	0.88
Number of inpatient days	88.47	235.25	101.55	216.23	13.1	0.28
Years of smoking (at baseline)	2.69	8.96	31.81	9.72	29.1	< 0.001
Annual income, €	34,060	22,180	27,510	17,730	-6,550	< 0.001
Occupational productivity lost due to smoking, €	0	0	34,370	27,080	34,370	< 0.001
Income taxes lost due to smoking, €	0	0	11,660	12,550	11,660	< 0.001
Annual pension, €	20,440	13,330	16,180	9,730	-4,260	< 0.001
Reduced pension costs due to smoking, €	0	0	126,850	148,120	126,850	< 0.001
Reduced income taxes paid from pensions, €	0	0	34,230	48,650	34,230	< 0.001
Annual health care costs/living individuals, €	3,420	9,870	5,040	10,650	1,620	0.003
Total health care costs, €	79,290	173,420	74,570	154,950	-4,720	0.59
Tobacco tax paid, €	2,190	8,860	50,300	32,450	48,110	< 0.001
Life years lost due to smoking, €	0	0	203,960	180,890	203,960	< 0.001
Total costs, life years lost not included, €	77,110	173,840	-56,680	195,130	-133,790	< 0.001
Total costs, life years lost included, €	77,110	173,840	147,280	195,960	70,170	< 0.001

Total costs of smoking vs. non-smoking were calculated by taking into account the life-long difference (€/person) of health care costs (€ 4,720), tobacco taxes paid (€ 48,110), income taxes lost (€ 11,660), reduced pension costs (€ 126,850), and reduced taxes paid from pensions (€ 34,230). The smoking-related harms for the society were € 11,660 + € 34,230 = € 45,890, and the smoking-related benefits for the society were € 4,720 + € 48,110 + € 126,850 = € 179,680, and thus the net effect on public finance balance was € 133,790 positive for each smoking individual. When the value of 9.19 life years lost due to smoking (€ 203,960) was taken into account, the net effect became € 70,170 negative for each smoking individual. "Income taxes lost due to smoking" indicate the loss due to earlier disability/retirement, and "Pension costs" indicate the pensions paid by the state and pension companies. The value of one quality adjusted life year lost was estimated to be $0.74 \times € 30,000 = € 22,200$.^{10,25}


Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.



er review only

BMJ Open: first published as 10.1136/bmjopen-2012-001678 on 11 December 2012. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).



er review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	Done	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2 pp. 3,4	Explain the scientific background and rationale for the investigation being reported
Objectives	3 p. 4	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4 p. 4	Present key elements of study design early in the paper
Setting	5 p. 4	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6 pp. 4,5	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7 pp. 4,5	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8* pp.4,5	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9 Not done	Describe any efforts to address potential sources of bias
Study size	10 p. 4	Explain how the study size was arrived at
Quantitative variables	11 pp. 4,5	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12 p. 5	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed No missing data
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses

Continued on next page

Results		
Participants	13* p. 4	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage No drop-outs or missing data (c) Consider use of a flow diagram
Descriptive data	14* Done	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Table 2 (b) Indicate number of participants with missing data for each variable of interest No missing data (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) p. 4
Outcome data	15* Done	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures Tables 1 and 2
Main results	16 Done	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses No such analyses
Discussion		
Key results	18 pp. 6, 7	Summarise key results with reference to study objectives
Limitations	19 pp. 8, 9	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20 p. 9	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21 p. 9	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22 p. 11	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



Smoking and healthcare and welfare costs. A Cohort Study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001678.R1
Article Type:	Research
Date Submitted by the Author:	20-Sep-2012
Complete List of Authors:	Tiihonen, Jari; University of Eastern Finland, Dept of Forensic Psychiatry; Karolinska Institutet, Dept of Clinical Neuroscience Ronkainen, Kimmo; University of Eastern Finland, Institute of Public Health and Clinical Nutrition Kangasharju, Aki; Government Institute for Economic Research, Kauhanen, Jussi; University of Eastern Finland, Institute of Public Health and Clinical Nutrition
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Epidemiology, Health economics
Keywords:	EPIDEMIOLOGY, HEALTH ECONOMICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

Word count for text only: 2863 words

Smoking and Healthcare and Welfare Costs. A Cohort Study.

Jari Tiihonen Professor and Chairman^{1,2,3}, Kimmo Ronkainen IT specialist⁴, Aki Kangasharju Director General⁵, Jussi Kauhanen Professor and Chairman⁴

Author Affiliations: ¹Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; ²National Institute for Health and Welfare, Helsinki, Finland; ³Departments of Psychiatry and Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital and Kuopio University Hospital, Kuopio, Finland; ⁴Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; ⁵Government Institute for Economic Research, Helsinki. Finland

Correspondence to: Prof. Jari Tiihonen, MD, PhD, Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Niuvankuja 65, FI-70240 Kuopio, Finland, tel. +358 17 203 202; fax: +358 17 203 494; jari.tiihonen@niuva.fi or jari.tiihonen@ki.se

Keywords: smoking; healthcare; costs; mortality

Submitted to BMJ Open, June 20, 2012; revised September 20, 2012

Abstract

Objective: To study the net economic effect of smoking on society.

Design, Setting, and Patients: We studied mortality, paid income and tobacco taxes, and the cumulative costs due to pensions and medical care among both tobacco smoking and non-smoking individuals in a 27-year prospective cohort study of 1,976 men from Eastern Finland. These individuals were 54–60 years old at the beginning of the follow-up.

Main Outcome Measures: The net contribution of smoking vs. non-smoking individuals to public finance balance (euros).

Results: Smoking was associated with a greater mean annual health care cost of €1,600 per living individual during follow-up. However, due to a shorter life span of 8.6 years, smokers' mean total healthcare costs during the entire study period were actually €4,700 lower than for non-smokers. For the same reason, each smoker missed 7.3 years (€126,850) of pension. Overall, smokers' average net contribution to the public finance balance was €133,800 greater per individual compared with non-smokers. However, if each lost quality adjusted life year is considered to be worth €22,200, the net effect is reversed to be €70,200 (€ 71.600 when adjusted with propensity score) per individual in favour of non-smoking.

Conclusion: Smoking was associated with a moderate decrease in health care costs, and a marked decrease in pension costs due to increased mortality. However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

Introduction

Smoking is the single most important preventable cause of premature death in industrialized countries¹, and tobacco taxation is still the most cost-effective method for decreasing the prevalence of smoking. Increases in tobacco taxes have encouraged 9 to 17% of smokers to quit^{2,3}, and in the long run the main effect of taxation is a reduction in the incidence of new young smokers.⁴ Early smoking cessation increases lifespan by about 9-10 years,⁵ and if the smoking rate diminished by 10 percentage points, life expectancy would increase by about one year. It has been estimated that a 10% increase in the price of smoked tobacco will result in about a 5% decrease in cigarette consumption,⁴ yet tobacco taxes are still low in many countries. Thus, it would be interesting to know why so many governments in the world continue to increase spending on health care costs, while a substantial savings and advances in life expectancy are readily available by administratively increasing tobacco taxes? There are two plausible explanations: the governments do not know about the correlation between increasing tobacco taxes on increasing life expectancy, or they realize this effect, but do not want to increase the life expectancy.

The net effect of smoking on healthcare costs has been investigated in several studies.⁶⁻¹⁸ Some modelling studies have suggested that while smokers suffer more from many kinds of diseases, non-smokers incur more healthcare costs because they live longer,^{6,7,8,11,12} yet others have reached the opposite conclusion.^{9,10,13-18} Only few of these studies have included both pension and insurance costs,^{7,12,17,18} and paid tobacco taxes.^{12,17,18} In 2001, Philip Morris provided a report to the Government of the Czech Republic, which indicated that the effect of smoking on the public finance balance in the Czech Republic in 1999 was positive and estimated to be 5,815 million korunas (about 150 million USD).¹² Although this report generated outraged reactions worldwide, Milos Zeman, the Czech prime minister stated "As a smoker, I support the state budget, because in the Czech Republic, we pay tax on tobacco. Also, smokers die sooner, and the state does not need to look after them in their old age".^{19,20} This report was based on many assumptions that were obtained through theoretical modelling, and it did not give any monetary value for life years lost because of smoking, and it was claimed to have underestimated the costs of medical care for people suffering from smoking related diseases.²¹ The overall net effect of smoking on

private (personal) and external costs has been studied also by Sloan et al¹⁷ and Viscusi¹⁸, who used US lifetable data to model the forth-coming lifelong net costs caused by smoking. As shown by van Baal et al., slightly different models can give markedly different results on the net effect of smoking, depending what assumptions are used²². In any case, sophisticated incidence-based datasets are ultimately required to establish the true health care costs incurred by smoking.²³ Because no results have been obtained from prospective, individual level data based on mortality, morbidity, pension and health care costs, the net economic impact of smoking on society has remained unclear. The aim of this study was to investigate this net economic effect by using data from a prospective 27-year follow-up of a cohort of 1,976 Finnish middle-aged men.

Methods

Study population

The subjects of the Kuopio Ischemic Heart Disease study (KIHD) were obtained from a randomly selected sample of 3,433 men, aged 42 to 60 years, who resided in the town of Kuopio or its surrounding rural communities. Of those invited, 2,682 (83 %) participated in the study. Of these, individuals from 54 to 60 years with complete data for smoking, income, healthcare costs, retirement, and mortality (n=1,976 men) were included in the final analyses. The baseline examinations were conducted between March 1984 and December 1989.²⁴ The mean follow-up time was 24.2 years (range 21.1±26.8 years). The KIHD study was approved by the Research Ethics Committee of the University of Kuopio, in Kuopio, Finland. Each participant gave written informed consent. The end of follow-up period was December 31, 2010.

A subject was defined as a smoker if he had ever smoked on a regular basis, and had smoked cigarettes, cigars, or a pipe within the past 30 days. The lifelong exposure to smoking ("cigarette pack-years") was estimated as the product of years smoked and the number of tobacco products smoked daily at the time of examination. "Years smoked" were defined as the sum of years of smoking regardless of when smoking had started, whether the subject had stopped smoking, or whether it had occurred continuously or during several periods. Data on mortality was obtained from Statistics Finland, and data on

1
2
3 healthcare costs from the Finnish Institute for Health and Welfare (THL). The health care
4 costs did not include visits to general practitioners, home nursing, or medication and dental
5 care costs in outpatient care, which have been estimated to be about 20–30% of total
6 health care costs in this age group in Finland.²⁵ The amount of paid tobacco taxes was
7 estimated on the basis of cigarette pack-years,²⁶ and the amount of paid income taxes was
8 estimated by using the income tax rate of year 1987. The amount of occupational
9 productivity and income taxes lost was calculated as the difference of age at retirement
10 (relative to the retirement age of matched non-smokers) multiplied by the annual income
11 and income tax of each smoker. “Income taxes paid” also included obligatory pension and
12 healthcare insurance fees. All monetary values were expressed as Euros (€) and
13 converted to the level of year 2009.
14
15
16
17
18
19
20
21
22

23 In the United Kingdom, the monetary value of one quality adjusted life year (QALY) has
24 been estimated to be 20,000–30,000 Pounds for an individual having perfect health.²⁷ In
25 the present study, we used a value of 30,000 Euros (about 25,100 Pounds in February
26 2012). In a recent large study on the effect of smoking on life expectancy, the quality-of-life
27 score among former smokers with a BMI of 25–30, who were older than 65-years was
28 estimated to be 0.71–0.77.²⁸ Therefore, we used a quality-of-life score of 0.74 for smokers
29 in the present study, thus equalling to 0.74 x 30,000 Euros = 22,200 Euros for each life
30 year lost due to smoking among former smokers aged over 65 years (deceased smokers
31 who would be over 65 if they had lived).
32
33
34
35
36
37
38
39
40
41
42

43 **Statistical analysis**

44 Differences in baseline characteristics and costs were examined using the Student’s t-test.
45 Descriptive data are presented as means and percentages. A p-value of less than 0.05
46 was considered statistically significant. These statistical analyses were performed using
47 SPSS 17.0 for Windows. Life expectancy for those individuals still alive on 31st December
48 2009 was calculated by using life expectancy from the Life Table provided by Statistics
49 Finland.²⁹
50
51
52
53
54

55 Adjusted group difference in total cost was assessed also using bootstrap type analysis of
56 covariance (ANCOVA) with adjustments for the propensity score. Potential variables for
57 inclusion in the propensity score (age at baseline, BMI, systolic blood pressure, LDL-
58
59
60

1
2
3 cholesterol and years of education) were explored in logistic regression with a backward
4 selection procedure ($P < 0.25$ as selection criterion). Patients were stratified based on
5 quintiles of the propensity score. Furthermore, the fit of the propensity score model was
6 assessed by the Hosmer–Lemeshow test.
7
8
9

10 11 Results

12
13
14 The crude mortality rates were 351/493 (71.2%) among smokers, and 553/1483 (37.3%)
15 among non-smokers, and the cause-specific mortality in each group is shown in Table 1.
16 The observed age at death was 67.8 years for smokers, and 71.4 years for non-smokers.
17 The predicted mean age at death was 72.1 for smokers and 80.7 years for non-smokers,
18 indicating 8.6 years difference between two groups. When the effect of birth year on life
19 expectancy was taken into account, the amount of life years lost due to smoking was 9.2
20 years. The demographic variables and smoking-related outcomes are shown in Table 2.
21 Smokers had substantially lower mean BMI and educational level. Smokers also had a
22 slightly lower mean systolic blood pressure and a slightly higher mean LDL cholesterol
23 level. Smoking was associated with a moderate decrease in productive occupational
24 career, income taxes paid, and hospital care costs, and showed a marked decrease in
25 pension costs. The net effect of smoking on public finance was plus € 133,800 for these
26 smokers during the follow-up when life years lost were not included, and minus € 70,200
27 when a monetary value for life years lost was included in the calculation. When propensity
28 score method was applied, the result remained almost the same (€ 71.600, 95%CI €
29 52.300 to € 90.800).
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Figure 1 demonstrates the average annual healthcare costs as a function of age among
44 those individuals still alive, and Figure 2 shows the corresponding results when all
45 individuals (also deceased) are included. The higher mortality results into lower annual
46 costs among smokers after 72 years from birth.
47
48
49
50

51 Discussion

52
53
54
55 Hospital care costs were 1,600 Euros greater per person year for living individuals among
56 the smokers during the follow-up, but due to a 8.6 year shorter life span, the total costs per
57
58
59
60

individual were 4,700 Euros lower among smokers than non-smokers during the entire study period. This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective, individual level data.

Smoking resulted in a moderate decrease in the productive occupational career and income taxes and pension fees paid, a moderate decrease in health care costs, and a marked decrease in the pension costs. The costs of smoking to society have been modelled by using estimates on increased mortality and morbidity.⁶⁻¹⁸ However, none of these modelling studies investigated the overall net economic effect of smoking on public finance balance by using actual data from individuals, and only few had taken into account all of the following factors; lifetime productivity or income taxes and pension fees paid, pension costs, and a monetary value of life years lost.^{17,18} Our results indicate that combined, these factors make considerable contribution to the overall net effect than merely health care costs which is in line with the modelling studies by Sloan et al.¹⁷ and Viscosi¹⁸. If the potential increase in quality adjusted life years is taken into account, our results suggest that the life long net beneficial economic effect of early smoking cessation is more than € 70,000 per individual, and this sum did not change substantially when propensity score was applied in the analysis. Our results also indicate that reducing the rate of smoking has a huge beneficial economic effect on society, mainly due to increased life span and continued pension costs. In Finland, the National Institute for Health and Welfare aims to make Finland free of smoking by the year 2040. Since there are currently about 900,000 smokers in Finland, the average net effect of € 134,000 per individual on public finance balance (without taking into account the monetary value of life years lost) would correspond during the next decades to about 120 billion Euros total increase in costs (over 2.5-fold to annual state budget). However, this nominal deficit would be massively outweighed by about 2 years increase in life expectancy of the whole nation.

Our overall results on the net economic effect of smoking on public finance balance are contrary to the Philip Morris report. A major reason for this difference is that Little did not consider the inherent value of the quality adjusted life years lost. In other words, if we used an estimate of 0 Euros for each lost year of human life, then the positive economic effect of smoking in our study would have been even larger than the effect estimated by Little. However, when considering the implications of these results, the major question is whether

1
2
3 or not humans are to be valued as commodities, like domesticated animals, or does human
4 life maintain an inherent value even when the individual is not longer economically
5 productive, as in retirement? In the field of health care, it is generally assumed that all
6 human life – even that of the old and disabled – is precious and has value. This view is
7 also currently accepted by national authorities throughout most of the modern world.
8 Already in 1999, 387 billion USD was used in the U.S. for medical treatment and care of
9 people older than 65 years.³⁰ Nowadays it is generally agreed that the monetary value of
10 one additional life year of a healthy human being is about 20,000-30,000 British Pounds
11 when additional costs of medical care are considered.²⁷ One may ask why societies
12 continue to invest even larger amounts of money and other social resources to achieve a
13 longer mean life span for citizens, while a more drastic increase could be achieved
14 administratively, without any further costs, by substantially raising tobacco taxes and
15 otherwise restricting access to smoking? There are two likely answers: either
16 governmental authorities have not realized this fact, or they have realized it, but do not
17 want to increase life expectancy due to a subsequent increase in both health care and
18 pension costs.
19
20
21
22
23
24
25
26
27
28
29
30

31 While denying access to medical care for older people, in order to prevent a deficit in
32 national economy, would not be possible because of common ethical concerns and public
33 opinion, preventing a decrease in smoking rates essentially has the same effect, and is
34 apparently more accepted by many societies. If this is the case, it would also explain the
35 reluctance of governments to regulate the eating and other consumption habits of that
36 negatively affect the general population by, for example, increasing the value added tax
37 (VAT) on food products that are high in sugar and saturated fats, and decreasing VAT on
38 fruits and vegetables, for example. The Czech prime minister stated in 2001 that smoking
39 is beneficial for the state, because smokers die sooner.^{17,18} Such comments have not been
40 echoed by other state leaders since, however it is plausible that this view still influences
41 tobacco policies in many modern countries. Therefore, governments should be transparent
42 concerning which kind of knowledge their tobacco and food taxation policy is based on.
43 Our study cannot answer the question on why cigarette taxes are still low in many
44 countries. Therefore, this remains open and a topic for further research.
45
46
47
48
49
50
51
52
53
54

55
56 The strength of this study is based on empirical data that was gathered from a 27-year
57 prospective study. Thus, no assumptions on healthcare, pension costs or discount
58
59
60

1
2
3 percentages of future costs were needed. One shortcoming is that this study did not
4 include females, and it did not include visits to general practitioners, home nursing, or
5 medication and dental care costs in outpatient care, which contribute to about 20–30% of
6 the total health care costs among elderly and middle aged people in Finland.²⁵ In a
7 previous 19-year follow-up study, it was observed that while the overall healthcare costs
8 were higher among smokers aged 25–59 years, the costs of medication in outpatient care
9 did not differ between smokers and non-smokers.³¹ Thus it can be further estimated that
10 the total health care costs might have been at the most about 6,000 to 7,000 Euros higher
11 per individual among non-smokers when compared with smokers, instead of our modest
12 estimate of about 5,000 Euros per individual. However, the magnitude of this difference
13 (€ 1,000–2,000) is less than 2% of the pension costs, and does not have any substantial
14 effect on these results. We also did not include the costs of fires or littering related to
15 smoking, as this information was not available, yet the combined contribution of these
16 factors is probably less than 1% of the total costs.¹² Since only 17% of the initiated
17 subjects refused to participate, the generalisability of results can be considered quite
18 sufficient.
19
20
21
22
23
24
25
26
27
28
29

30
31 It was presumed that smokers' lower education level and lower income level were not
32 caused by smoking, and that differences in these characteristics were associated with
33 smoking due to the fact that less educated individuals are more likely to start smoking than
34 individuals with higher educational level. Therefore, it was assumed that smoking
35 cessation would not substantially increase education level or income. It can be estimated
36 that during a productive career of about 35 years, with an annual difference of € 2,970 in
37 paid income taxes, smokers in our study have paid an average about 100,000 Euros less
38 income taxes than non-smokers. If it were assumed that early smoking cessation would
39 change these variables to the same levels as with non-smokers, the net difference
40 between smokers vs. non-smokers would shift from € 134,000 to about € 30,000 in favour
41 of smoking, if the value of life years lost are not included, and from € 70,000 to about €
42 170,000 in favour of non-smoking if the value of life years lost are included in the analysis.
43 Either way, the principal conclusions on the net costs would remain the same. It is
44 questionable if the tobacco taxes should be considered as beneficial increases in income
45 to the state. For example, if an individual would not have been smoking, then he/she
46 probably would have consumed more goods in the extra years of life and thus paid more
47 taxes for those goods instead of the taxes paid for cigarettes. Overall, the estimate of a €
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 70,000 beneficial effect of early smoking cessation per individual is probably an
4 underestimate.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article summary

1) Article Focus

- No results have been obtained from prospective individual level data based on mortality, morbidity, pension and health care costs and, therefore, the net economic impact of smoking on society has remained unclear.

2) Key Messages

- Both the healthcare and pension costs are lower for smokers than non-smokers, the overall difference being more than 100,000 euros per individual.
- However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

3) Strengths and Limitations

- This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective data from individual subjects.
- Only males were included in study.

Funding/Support: This project was funded by the Ministry of Health and Social Affairs (Finland), the National Institute for Health and Welfare (THL) and the Academy of Finland. The funders were not involved in the conduct of the study, or in the collection, management, analysis or interpretation of the data.

Competing Interest: All authors have completed the Unified Competing Interest form at www.icmj.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: Dr Tiihonen is a member of advisory board of AstraZeneca and Janssen-Cilag, and he reports serving as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, and lecture fees from Janssen-Cilag, Bristol Myers-Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, Novartis, and Astra Zeneca. No further disclosures were reported.

Contributors: JT, KR and JK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JT wrote the first draft of the manuscript and all other authors read and had input in the final version of the paper. JT did study concept and design, KR and JK collected data, KR did statistical analysis and KR produced figures. JT is the guarantor.

Ethical approval: The KIHD study was approved by the Research Ethics Committee of the University of Kuopio, in Kuopio, Finland.

Data sharing: No additional data available.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).

References

- 1 Schroeder SA, Warner KE. Don't forget tobacco. *N Engl J Med* 2010;363:201-4.
- 2 Dunlop SM, Cotter TF, Perez DA. Impact of the 2010 tobacco tax increase in Australia on short-term smoking cessation: a continuous tracking survey. *Med J Aust* 2011;195:469-72.
- 3 Choi TC, Toomey TL, Chen V, *et al.* Awareness and reported consequences of a cigarette tax increase among older adolescents and young adults. *Am J Health Promot* 2011;25:379-86.
- 4 Gallet CA, List JA. Cigarette demand: a meta-analysis of elasticities. *Health Economics* 2003;12:821-35.
- 5 Doll R, Peto R, Boreham J, *et al.* Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
- 6 Leu RE, Schaub T. Does smoking increase medical care expenditure? *Soc Sci Med* 1983;17:1907-14.
- 7 Manning WG, Keeler EB, Newhouse JP, *et al.* The taxes of sin. Do smokers and drinkers pay their way? *JAMA* 1989;261:1604-9.
- 8 Lippiatt BC. Measuring medical cost and life expectancy impacts of changes in cigarette sales. *Prev Med* 1990;19:515-32.
- 9 MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco use. *N Engl J Med* 1994;330:975-80.
- 10 Smoking-related deaths and financial costs: estimates for 1990. Rev. ed. Washington, DC: Office of Technology Assessment, 1993.
- 11 Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. *N Engl J Med* 1997;337:1052-7.
- 12 Arthur D. Little International, Inc. Philip Morris funded study of smoking in the Czech Republic stating that the Czech government had a net gain of \$147.1 million from smoking. <http://www.mindfully.org/Industry/Philip-Morris-Czech-Study.htm>. Accessed November 21, 2011.
- 13 Yang L, Sung HY, Mao Z, *et al.* Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. *Tob Control* 2011;20:266-72.

- 1
2
3 14 Callum C, Boyle S, Sandford A. Estimating the cost of smoking to the NHS in
4 England and the impact of declining prevalence. *Health Econ Policy Law* 2011;6:489-
5 508.
6
7
8 15 Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. *Soc*
9 *Sci Med* 1999;48:375-91.
10
11 16 Miller LS, Max W, Sung HY, *et al.* Evaluation of the economic impact of California's
12 Tobacco Control Program: a dynamic model approach. *Tob Control* 2010;19(Suppl
13 1):i68-i76.
14
15
16 17 Sloan FA, Ostermann J, Picone G, Conover C, Taylor DH Jr. The Price of Smoking.
17 The MIT Press: Cambridge, Massachusetts, London, England 2004.
18
19 18 Viscusi WK. The Governmental Composition of the Insurance Costs of Smoking. *J*
20 *Law Economics* 1999 ;42 :574-609
21
22 19 L'Organisation mondiale de la Santé. Guide pour la mise en place de l'action
23 antitabac. 2006, p. 21.
24
25 20 Holley David (August 05, 2001): "Philip Morris Angers Czechs With Tobacco Toll
26 Report – Los Angeles Times" ([http://articles.latimes.com/2001/aug/05/news/mn-](http://articles.latimes.com/2001/aug/05/news/mn-30831)
27 30831). Los Angeles Times. Accessed December 12, 2011.
28
29 21 <http://www.tobacco.org/news/70612.html>. Accessed December 23, 2011.
30
31 22 van Baal PH, Feenstra TL, Polder JJ, *et al.* Economic evaluation and the
32 postponement of health care costs. *Health Econ* 2011;20:432-45.
33
34 23 Heaney D. The health care costs of smoking. *N Engl J Med* 1998;338:471; author
35 reply 472.
36
37 24 Lakka TA, Venäläinen JM, Rauramaa R, *et al.* Relation of leisure-time physical
38 activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men.
39 *N Engl J Med* 1994;330:1549-54.
40
41 25 Kuntaliitto. Suurten kaupunkien terveydenhuollon kustannukset vuonna 2010.
42 Helsinki: Suomen kuntaliitto, 2011.
43
44 26 Official Statistics of Finland. Tobacco Statistics 2009. Helsinki: Statistics Finland,
45 2010.
46
47 27 National Institute for Health and Clinical Excellence. Measuring effectiveness and
48 cost effectiveness: the QALY.
49 [http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivene](http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp)
50 [sstheqaly.jsp](http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp). Accessed December 12, 2011.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28 Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on
4 U.S. life expectancy. *N Engl J Med* 2009;361:2252-60.
5
6 29 Statistics Finland. Life Table 2007/Life expectancy of men, by age. Statistics Finland.
7 <http://www.staft.fi/til/kuol/tau.html>. Accessed February 9, 2012.
8
9 30 Keehan SP, Lazenby HC, Zezza MA, et al. Age Estimates in the National Health
10 Accounts. *Health Care Financing Review* 2004 Dec. 2; 1(1); Web Exclusive.
11
12 31 Kiiskinen U, Vartiainen E, Puska P, et al. Smoking-related costs among 25 to 59
13 year-old males in a 19-year individual follow-up. *Eur J Publ Health* 2002;12:145-51.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Cause-specific mortality among smokers and non-smokers.

Cause of death	Non-smokers (%)	Smokers (%)
Cardiovascular disease	267 (48%)	166 (47%)
Cancer (all)	146 (26%)	102 (29%)
Lung cancer	15 (3%)	47 (13%)
Respiratory disease	13 (2%)	20 (6%)
External causes of death	56 (10%)	28 (8%)
Other	71 (13%)	35 (10%)
Total	553 (100%)	351 (100%)


A total of 553 (37.3%) non-smokers and 351 (71.2%) smokers had died during the follow-up. Percentages indicate the proportions for cause of death from all deaths in each group. Cancer deaths include lung cancer deaths.

Table 2. Smoking-related outcomes.

	Non-smokers N=1483		Smokers N=493		Difference of means	p-value
	Mean	S.D.	Mean	S.D.		
Age at baseline, years	55.72	2.50	55.54	2.38	-0.2	0.17
Body mass index (BMI)	27.29	3.51	26.01	3.81	-1.3	< 0.001
Mean systolic blood pressure (mm Hg)	135.93	17.43	133.43	18.18	-2.5	0.007
LDL-cholesterol (mmol/l)	4.07	1.01	4.21	1.09	0.1	0.013
Years of education	8.19	3.32	7.52	2.74	-0.7	< 0.001
Age at death, years	80.71	8.40	72.13	8.89	-8.6	< 0.001
Life years lost due to smoking	0	0	9.19	8.15	9.2	< 0.001
Age at retirement, years	56.60	5.89	55.35	6.23	-1.3	< 0.001
Years of receiving pension	23.69	9.11	16.42	9.39	-7.3	< 0.001
Number of hospitalizations	10.74	12.34	10.84	10.89	0.1	0.88
Number of inpatient days	88.47	235.25	101.55	216.23	13.1	0.28
Years of smoking (at baseline)	2.69	8.96	31.81	9.72	29.1	< 0.001
Annual income, €	34,060	22,180	27,510	17,730	-6,550	< 0.001
Occupational productivity lost due to smoking, €	0	0	34,370	27,080	34,370	< 0.001
Income taxes lost due to smoking, €	0	0	11,660	12,550	11,660	< 0.001
Annual pension, €	20,440	13,330	16,180	9,730	-4,260	< 0.001
Reduced pension costs due to smoking, €	0	0	126,850	148,120	126,850	< 0.001
Reduced income taxes paid from pensions, €	0	0	34,230	48,650	34,230	< 0.001
Annual health care costs/living individuals, €	3,420	9,870	5,040	10,650	1,620	0.003
Total health care costs, €	79,290	173,420	74,570	154,950	-4,720	0.59
Tobacco tax paid, €	2,190	8,860	50,300	32,450	48,110	< 0.001
Life years lost due to smoking, €	0	0	203,960	180,890	203,960	< 0.001
Total costs, life years lost not included, €	77,110	173,840	-56,680	195,130	-133,790	< 0.001
Total costs, life years lost included, €	77,110	173,840	147,280	195,960	70,170	< 0.001

Total costs of smoking vs. non-smoking were calculated by taking into account the life-long difference (€/person) of health care costs (€ 4,720), tobacco taxes paid (€ 48,110), income taxes lost (€ 11,660), reduced pension costs (€ 126,850), and reduced taxes paid from pensions (€ 34,230). The smoking-related harms for the society were € 11,660 + € 34,230 = € 45,890, and the smoking-related benefits for the society were € 4,720 + € 48,110 + € 126,850 = € 179,680, and thus the net effect on public finance balance was € 133,790 positive for each smoking individual. When the value of 9.19 life years lost due to smoking (€ 203,960) was taken into account, the net effect became € 70,170 negative for each smoking individual. "Income taxes lost due to smoking" indicate the loss due to earlier disability/retirement, and "Pension costs" indicate the pensions paid by the state and pension companies. The value of one quality adjusted life year lost was estimated to be $0.74 \times € 30,000 = € 22,200$.^{10,25}


Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

er review only

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).



er review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

Word count for text only: **28632716** words

Smoking and Healthcare and Welfare Costs. A Cohort Study.

Jari Tiihonen Professor and Chairman^{1,2,3}, Kimmo Ronkainen IT specialist⁴, Aki Kangasharju Director General⁵, Jussi Kauhanen Professor and Chairman⁴

Author Affiliations: ¹Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; ²National Institute for Health and Welfare, Helsinki, Finland; ³Departments of Psychiatry and Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital and Kuopio University Hospital, Kuopio, Finland; ⁴Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; ⁵Government Institute for Economic Research, Helsinki, Finland

Correspondence to: Prof. Jari Tiihonen, MD, PhD, Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Niuvankuja 65, FI-70240 Kuopio, Finland, tel. +358 17 203 202; fax: +358 17 203 494; jari.tiihonen@niuva.fi or jari.tiihonen@ki.se

Keywords: smoking; healthcare; costs; mortality

Submitted to BMJ Open, June 20, 2012; **revised September 20, 2012**

Abstract

Objective: To study the net economic effect of smoking on society.

Design, Setting, and Patients: We studied mortality, paid income and tobacco taxes, and the cumulative costs due to pensions and medical care among both tobacco smoking and non-smoking individuals in a 27-year prospective cohort study of 1,976 men from Eastern Finland. These individuals were 54–60 years old at the beginning of the follow-up.

Main Outcome Measures: The net contribution of smoking vs. non-smoking individuals to public finance balance (euros).

Results: Smoking was associated with a greater mean annual health care cost of €1,600 per living individual during follow-up. However, due to a shorter life span of 8.6 years, smokers' mean total healthcare costs during the entire study period were actually €4,700 lower than for non-smokers. For the same reason, each smoker missed 7.3 years (€126,850) of pension. Overall, smokers' average net contribution to the public finance balance was €133,800 greater per individual compared with non-smokers. However, if each lost quality adjusted life year is considered to be worth €22,200, the net effect is reversed to be €70,200 (€ 71.600 when adjusted with propensity score) per individual in favour of non-smoking.

Conclusion: Smoking was associated with a moderate decrease in health care costs, and a marked decrease in pension costs due to increased mortality. However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

Introduction

Smoking is the single most important preventable cause of premature death in industrialized countries¹, and tobacco taxation is still the most cost-effective method for decreasing the prevalence of smoking. Increases in tobacco taxes have encouraged 9 to 17% of smokers to quit^{2,3}, and in the long run the main effect of taxation is a reduction in the incidence of new young smokers.⁴ Early smoking cessation increases lifespan by about 9-10 years,⁵ and if the smoking rate diminished by 10 percentage points, life expectancy would increase by about one year. It has been estimated that a 10% increase in the price of smoked tobacco will result in about a 5% decrease in cigarette consumption,⁴ yet tobacco taxes are still low in many countries. Thus, it would be interesting to know why so many governments in the world continue to increase spending on health care costs, while a substantial savings and advances in life expectancy are readily available by administratively increasing tobacco taxes? There are two plausible explanations: the governments do not know about the correlation between increasing tobacco taxes on increasing life expectancy, or they realize this effect, but do not want to increase the life expectancy.

The net effect of smoking on healthcare costs has been investigated in several studies.⁶⁻¹⁸ Some modelling studies have suggested that while smokers suffer more from many kinds of diseases, non-smokers incur more healthcare costs because they live longer,^{6,7,8,11,12} yet others have reached the opposite conclusion.^{9,10,13-18} Only ~~two~~ few of these studies have included both pension and insurance costs,^{7,12,17,18} and ~~only one study has included~~ paid tobacco taxes.^{12,17,18} In 2001, Philip Morris provided a report to the Government of the Czech Republic, which indicated that the effect of smoking on the public finance balance in the Czech Republic in 1999 was positive and estimated to be 5,815 million korunas (about 150 million USD).¹² Although this report generated outraged reactions worldwide, Milos Zeman, the Czech prime minister stated "As a smoker, I support the state budget, because in the Czech Republic, we pay tax on tobacco. Also, smokers die sooner, and the state does not need to look after them in their old age".^{19,20} ~~To our knowledge, the Philip Morris report is the only published study thus far on the overall effect of smoking on the balance of public finance.~~ This report was based on many assumptions that were obtained through theoretical modelling, and it did not give any monetary value for life years lost because of

4

smoking, and it was claimed to have underestimated the costs of medical care for people suffering from smoking related diseases.²¹ The overall net effect of smoking on private (personal) and external costs has been studied also by Sloan et al¹⁷ and Viscusi¹⁸, who used US lifetable data to model the forth-coming lifelong net costs caused by smoking. As shown by van Baal et al., slightly different models can give markedly different results on the net effect of smoking, depending what assumptions are used²². In any case, sophisticated incidence-based datasets are ultimately required to establish the true health care costs incurred by smoking.²³ Because no results have been obtained from empirical/prospective, individual level data based on mortality, morbidity, pension and health care costs, the net economic impact of smoking on society has remained unclear. The aim of this study was to investigate this net economic effect by using data from a prospective 27-year follow-up of a cohort of 1,976 Finnish middle-aged men.

Comment [r1]: Reviewer 1

Methods

Study population

The subjects of the Kuopio Ischemic Heart Disease study (KIHD) were obtained from a randomly selected sample of 3,433 men, aged 42 to 60 years, who resided in the town of Kuopio or its surrounding rural communities. Of those invited, 2,682 (83 %) participated in the study. Of these, individuals from 54 to 60 years with complete data for smoking, income, healthcare costs, retirement, and mortality (n=1,976 men) were included in the final analyses. The baseline examinations were conducted between March 1984 and December 1989.²⁴ The mean follow-up time was 24.2 years (range 21.1±26.8 years). The KIHD study was approved by the Research Ethics Committee of the University of Kuopio, in Kuopio, Finland. Each participant gave written informed consent. The end of follow-up period was December 31, 2010.

A subject was defined as a smoker if he had ever smoked on a regular basis, and had smoked cigarettes, cigars, or a pipe within the past 30 days. The lifelong exposure to smoking ("cigarette pack-years") was estimated as the product of years smoked and the number of tobacco products smoked daily at the time of examination. "Years smoked" were defined as the sum of years of smoking regardless of when smoking had started,

whether the subject had stopped smoking, or whether it had occurred continuously or during several periods. Data on mortality was obtained from Statistics Finland, and data on healthcare costs from the Finnish Institute for Health and Welfare (THL). The health care costs did not include visits to general practitioners, home nursing, or medication and dental care costs in outpatient care, which have been estimated to be about 20–30% of total health care costs in this age group in Finland.²⁵ The amount of paid tobacco taxes was estimated on the basis of cigarette pack-years,²⁶ and the amount of paid income taxes was estimated by using the income tax rate of year 1987. The amount of occupational productivity and income taxes lost was calculated as the difference of age at retirement (relative to the retirement age of matched non-smokers) multiplied by the annual income and income tax of each smoker. “Income taxes paid” also included obligatory pension and healthcare insurance fees. All monetary values were expressed as Euros (€) and converted to the level of year 2009.

In the United Kingdom, the monetary value of one quality adjusted life year (QALY) has been estimated to be 20,000–30,000 Pounds for an individual having perfect health.²⁷ In the present study, we used a value of 30,000 Euros (about 25,100 Pounds in February 2012). In a recent large study on the effect of smoking on life expectancy, the quality-of-life score among former smokers with a BMI of 25–30, who were older than 65-years was estimated to be 0.71–0.77.²⁸ Therefore, we used a quality-of-life score of 0.74 for smokers in the present study, thus equalling to $0.74 \times 30,000$ Euros = 22,200 Euros for each life year lost due to smoking among former smokers aged over 65 years (deceased smokers who would be over 65 if they had lived).

Statistical analysis

Differences in baseline characteristics and costs were examined using the Student's t-test. Descriptive data are presented as means and percentages. A p-value of less than 0.05 was considered statistically significant. These statistical analyses were performed using SPSS 17.0 for Windows. Life expectancy for those individuals still alive on 31st December 2009 was calculated by using life expectancy from the Life Table provided by Statistics Finland.²⁹

6

Adjusted group difference in total cost was assessed also using bootstrap type analysis of covariance (ANCOVA) with adjustments for the propensity score. Potential variables for inclusion in the propensity score (age at baseline, BMI, systolic blood pressure, LDL-cholesterol and years of education) were explored in logistic regression with a backward selection procedure ($P < 0.25$ as selection criterion). Patients were stratified based on quintiles of the propensity score. Furthermore, the fit of the propensity score model was assessed by the Hosmer–Lemeshow test.

Comment [r2]: Reviewer 1

Results

The crude mortality rates were 351/493 (71.2%) among smokers, and 553/1483 (37.3%) among non-smokers, and the cause-specific mortality in each group is shown in Table 1. The observed age at death was 67.8 years for smokers, and 71.4 years for non-smokers. The predicted mean age at death was 72.1 for smokers and 80.7 years for non-smokers, indicating 8.6 years difference between two groups. When the effect of birth year on life expectancy was taken into account, the amount of life years lost due to smoking was 9.2 years. The demographic variables and smoking-related outcomes are shown in Table 2. Smokers had substantially lower mean BMI and educational level. Smokers also had a slightly lower mean systolic blood pressure and a slightly higher mean LDL cholesterol level. Smoking was associated with a moderate decrease in productive occupational career, income taxes paid, and hospital care costs, and showed a marked decrease in pension costs. The net effect of smoking on public finance was plus € 133,800 for these smokers during the follow-up when life years lost were not included, and minus € 70,200 when a monetary value for life years lost was included in the calculation. When propensity score method was applied, the result remained almost the same (€ 71.600, 95%CI € 52.300 to € 90.800).

Comment [r3]: Reviewer 1

Figure 1 demonstrates the average annual healthcare costs as a function of age among those individuals still alive, and Figure 2 shows the corresponding results when all individuals (also deceased) are included. The higher mortality results into lower annual costs among smokers after 72 years from birth.

Discussion

7

Hospital care costs were 1,600 Euros greater per person year for living individuals among the smokers during the follow-up, but due to a 8.6 year shorter life span, the total costs per individual were 4,700 Euros lower among smokers than non-smokers during the entire study period. This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective, individual level data.

Smoking resulted in a moderate decrease in the productive occupational career and income taxes and pension fees paid, a moderate decrease in health care costs, and a marked decrease in the pension costs. The costs of smoking to society have been modelled by using estimates on increased mortality and morbidity.⁶⁻¹⁸ However, none of these modelling studies investigated the overall net economic effect of smoking on public finance balance by using actual data from individuals, and only few had taken into account all of the following factors; lifetime productivity or income taxes and pension fees paid, pension costs, and a monetary value of life years lost.^{17,18} Our results indicate that combined, these factors make considerable contribution to the overall net effect than merely health care costs which is in line with the modelling studies by Sloan et al.¹⁷ and Viscosi¹⁸. If the potential increase in quality adjusted life years is taken into account, our results suggest that the life long net beneficial economic effect of early smoking cessation is more than € 70,000 per individual, and this sum did not change substantially when propensity score was applied in the analysis. Our results also indicate that reducing the rate of smoking has a huge beneficial economic effect on society, mainly due to increased life span and continued pension costs. In Finland, the National Institute for Health and Welfare aims to make Finland free of smoking by the year 2040. Since there are currently about 900,000 smokers in Finland, the average net effect of € 134,000 per individual on public finance balance (without taking into account the monetary value of life years lost) would correspond during the next decades to about 120 billion Euros total increase in costs (over 2.5-fold to annual state budget). However, this nominal deficit would be massively outweighed by about 2 years increase in life expectancy of the whole nation.

Our overall results on the net economic effect of smoking on public finance balance are contrary to the Philip Morris report. A major reason for this difference is that Little did not consider the inherent value of the quality adjusted life years lost. In other words, if we used

Comment [r4]: Reviewer 1

Comment [r5]: Reviewer 1

8

an estimate of 0 Euros for each lost year of human life, then the positive economic effect of smoking in our study would have been even larger than the effect estimated by Little. However, when considering the implications of these results, the major question is whether or not humans are to be valued as commodities, like domesticated animals, or does human life maintain an inherent value even when the individual is not longer economically productive, as in retirement? In the field of health care, it is generally assumed that all human life – even that of the old and disabled – is precious and has value. This view is also currently accepted by national authorities throughout most of the modern world. Already in 1999, 387 billion USD was used in the U.S. for medical treatment and care of people older than 65 years.³⁰ Nowadays it is generally agreed that the monetary value of one additional life year of a healthy human being is about 20,000-30,000 British Pounds when additional costs of medical care are considered.²⁷ One may ask why societies continue to invest even larger amounts of money and other social resources to achieve a longer mean life span for citizens, while a more drastic increase could be achieved administratively, without any further costs, by substantially raising tobacco taxes and otherwise restricting access to smoking? There are two likely answers: either governmental authorities have not realized this fact, or they have realized it, but do not want to increase life expectancy due to a subsequent increase in both health care and pension costs.

While denying access to medical care for older people, in order to prevent a deficit in national economy, would not be possible because of common ethical concerns and public opinion, preventing a decrease in smoking rates essentially has the same effect, and is apparently more accepted by many societies. If this is the case, it would also explain the reluctance of governments to regulate the eating and other consumption habits of that negatively affect the general population by, for example, increasing the value added tax (VAT) on food products that are high in sugar and saturated fats, and decreasing VAT on fruits and vegetables, for example. The Czech prime minister stated in 2001 that smoking is beneficial for the state, because smokers die sooner.^{17,18} Such comments have not been echoed by other state leaders since, however it is plausible that this view still influences tobacco policies in many modern countries. Therefore, governments should be transparent concerning which kind of knowledge their tobacco and food taxation policy is based on.

Our study cannot answer the question on why cigarette taxes are still low in many countries. Therefore, this remains open and a topic for further research.

Comment [r6]: Reviewer 2

1
2
3
4
5
6
7
8
9 The strength of this study is based on empirical data that was gathered from a 27-year
10 prospective study. Thus, no assumptions on healthcare, pension costs or discount
11 percentages of future costs were needed. One shortcoming is that this study did not
12 include females, and it did not include visits to general practitioners, home nursing, or
13 medication and dental care costs in outpatient care, which contribute to about 20–30% of
14 the total health care costs among elderly and middle aged people in Finland.²⁵ In a
15 previous 19-year follow-up study, it was observed that while the overall healthcare costs
16 were higher among smokers aged 25–59 years, the costs of medication in outpatient care
17 did not differ between smokers and non-smokers.³¹ Thus it can be further estimated that
18 the total health care costs might have been at the most about 6,000 to 7,000 Euros higher
19 per individual among non-smokers when compared with smokers, instead of our modest
20 estimate of about 5,000 Euros per individual. However, the magnitude of this difference
21 (€ 1,000–2,000) is less than 2% of the pension costs, and does not have any substantial
22 effect on these results. We also did not include the costs of fires or littering related to
23 smoking, as this information was not available, yet the combined contribution of these
24 factors is probably less than 1% of the total costs.¹² Since only 17% of the initiated
25 subjects refused to participate, the generalisability of results can be considered quite
26 sufficient.
27
28
29
30
31
32
33

34
35 It was presumed that smokers' lower education level and lower income level were not
36 caused by smoking, and that differences in these characteristics were associated with
37 smoking due to the fact that less educated individuals are more likely to start smoking than
38 individuals with higher educational level. Therefore, it was assumed that smoking
39 cessation would not substantially increase education level or income. It can be estimated
40 that during a productive career of about 35 years, with an annual difference of € 2,970 in
41 paid income taxes, smokers in our study have paid an average about 100,000 Euros less
42 income taxes than non-smokers. If it were assumed that early smoking cessation would
43 change these variables to the same levels as with non-smokers, the net difference
44 between smokers vs. non-smokers would shift from € 134,000 to about € 30,000 in favour
45 of smoking, if the value of life years lost are not included, and from € 70,000 to about €
46 170,000 in favour of non-smoking if the value of life years lost are included in the analysis.
47 Either way, the principal conclusions on the net costs would remain the same. It is
48 questionable if the tobacco taxes should be considered as beneficial increases in income
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 to the state. For example, if an individual would not have been smoking, then he/she
9 probably would have consumed more goods in the extra years of life and thus paid more
10 taxes for those goods instead of the taxes paid for cigarettes. Overall, the estimate of a €
11 70,000 beneficial effect of early smoking cessation per individual is probably an
12 underestimate.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10

For peer review only

Article summary

1) Article Focus

- No results have been obtained from prospective individual level data based on mortality, morbidity, pension and health care costs and, therefore, the net economic impact of smoking on society has remained unclear.

2) Key Messages

- Both the healthcare and pension costs are lower for smokers than non-smokers, the overall difference being more than 100,000 euros per individual.
- However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

3) Strengths and Limitations

- This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective data from individual subjects.
- Only males were included in study.

Funding/Support: This project was funded by the Ministry of Health and Social Affairs (Finland), the National Institute for Health and Welfare (THL) and the Academy of Finland. The funders were not involved in the conduct of the study, or in the collection, management, analysis or interpretation of the data.

Competing Interest: All authors have completed the Unified Competing Interest form at www.icmj.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: Dr Tiihonen is a member of advisory board of AstraZeneca and Janssen-Cilag, and he reports serving as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, and lecture fees from Janssen-Cilag, Bristol Myers-Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, Novartis, and Astra Zeneca. No further disclosures were reported.

Contributors: JT, KR and JK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JT wrote the first draft of the manuscript and all other authors read and had input in the final version of the paper. JT did study concept and design, KR and JK collected data, KR did statistical analysis and KR produced figures. JT is the guarantor.

Ethical approval: The KIHHD study was approved by the Research Ethics Committee of the University of Kuopio, in Kuopio, Finland.

Data sharing: No additional data available.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).

References

- 1 Schroeder SA, Warner KE. Don't forget tobacco. *N Engl J Med* 2010;363:201-4.
- 2 Dunlop SM, Cotter TF, Perez DA. Impact of the 2010 tobacco tax increase in Australia on short-term smoking cessation: a continuous tracking survey. *Med J Aust* 2011;195:469-72.
- 3 Choi TC, Toomey TL, Chen V, *et al.* Awareness and reported consequences of a cigarette tax increase among older adolescents and young adults. *Am J Health Promot* 2011;25:379-86.
- 4 Gallet CA, List JA. Cigarette demand: a meta-analysis of elasticities. *Health Economics* 2003;12:821-35.
- 5 Doll R, Peto R, Boreham J, *et al.* Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
- 6 Leu RE, Schaub T. Does smoking increase medical care expenditure? *Soc Sci Med* 1983;17:1907-14.
- 7 Manning WG, Keeler EB, Newhouse JP, *et al.* The taxes of sin. Do smokers and drinkers pay their way? *JAMA* 1989;261:1604-9.
- 8 Lippiatt BC. Measuring medical cost and life expectancy impacts of changes in cigarette sales. *Prev Med* 1990;19:515-32.
- 9 MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco use. *N Engl J Med* 1994;330:975-80.
- 10 Smoking-related deaths and financial costs: estimates for 1990. Rev. ed. Washington, DC: Office of Technology Assessment, 1993.
- 11 Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. *N Engl J Med* 1997;337:1052-7.
- 12 Arthur D. Little International, Inc. Philip Morris funded study of smoking in the Czech Republic stating that the Czech government had a net gain of \$147.1 million from smoking. <http://www.mindfully.org/Industry/Philip-Morris-Czech-Study.htm>. Accessed November 21, 2011.
- 13 Yang L, Sung HY, Mao Z, *et al.* Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. *Tob Control* 2011;20:266-72.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 14 Callum C, Boyle S, Sandford A. Estimating the cost of smoking to the NHS in England and the impact of declining prevalence. *Health Econ Policy Law* 2011;6:489-508.
- 15 Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. *Soc Sci Med* 1999;48:375-91.
- 16 Miller LS, Max W, Sung HY, *et al*. Evaluation of the economic impact of California's Tobacco Control Program: a dynamic model approach. *Tob Control* 2010;19(Suppl 1):i68-i76.
- 17 [17 Sloan FA, Ostermann J, Picone G, Conover C, Taylor DH Jr. The Price of Smoking. The MIT Press: Cambridge, Massachusetts, London, England 2004.](#)
- 18 [18 Viscusi WK. The Governmental Composition of the Insurance Costs of Smoking. *J Law Economics* 1999 ;42 :574-609](#)
- 19 L'Organisation mondiale de la Santé. Guide pour la mise en place de l'action antitabac. 2006, p. 21.
- 20 Holley David (August 05, 2001): "Philip Morris Angers Czechs With Tobacco Toll Report – Los Angeles Times" (<http://articles.latimes.com/2001/aug/05/news/mn-30831>). Los Angeles Times. Accessed December 12, 2011.
- 21 <http://www.tobacco.org/news/70612.html>. Accessed December 23, 2011.
- 22 van Baal PH, Feenstra TL, Polder JJ, *et al*. Economic evaluation and the postponement of health care costs. *Health Econ* 2011;20:432-45.
- 23 Heaney D. The health care costs of smoking. *N Engl J Med* 1998;338:471; author reply 472.
- 24 Lakka TA, Venäläinen JM, Rauramaa R, *et al*. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. *N Engl J Med* 1994;330:1549-54.
- 25 Kuntaliitto. Suurten kaupunkien terveydenhuollon kustannukset vuonna 2010. Helsinki: Suomen kuntaliitto, 2011.
- 26 Official Statistics of Finland. Tobacco Statistics 2009. Helsinki: Statistics Finland, 2010.
- 27 National Institute for Health and Clinical Excellence. Measuring effectiveness and cost effectiveness: the QALY. <http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp>. Accessed December 12, 2011.

- 1
2
3
4
5
6
7
8 28 Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on
9 U.S. life expectancy. *N Engl J Med* 2009;361:2252-60.
10
11 29 Statistics Finland. Life Table 2007/Life expectancy of men, by age. Statistics Finland.
12 <http://www.staf.fi/til/kuol/tau.html>. Accessed February 9, 2012.
13
14 30 Keehan SP, Lazenby HC, Zezza MA, et al. Age Estimates in the National Health
15 Accounts. *Health Care Financing Review* 2004 Dec. 2; 1(1); Web Exclusive.
16
17 31 Kiiskinen U, Vartiainen E, Puska P, et al. Smoking-related costs among 25 to 59
18 year-old males in a 19-year individual follow-up. *Eur J Publ Health* 2002;12:145-51.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

16

Figure legends

Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).

Table 1. Cause-specific mortality among smokers and non-smokers.

Cause of death	Non-smokers (%)	Smokers (%)
Cardiovascular disease	267 (48%)	166 (47%)
Cancer (all)	146 (26%)	102 (29%)
Lung cancer	15 (3%)	47 (13%)
Respiratory disease	13 (2%)	20 (6%)
External causes of death	56 (10%)	28 (8%)
Other	71 (13%)	35 (10%)
Total	553 (100%)	351 (100%)


A total of 553 (37.3%) non-smokers and 351 (71.2%) smokers had died during the follow-up. Percentages indicate the proportions for cause of death from all deaths in each group. Cancer deaths include lung cancer deaths.

Table 2. Smoking-related outcomes.


	Non-smokers N=1483		Smokers N=493		Difference of means	p-value
	Mean	S.D.	Mean	S.D.		
Age at baseline, years	55.72	2.50	55.54	2.38	-0.2	0.17
Body mass index (BMI)	27.29	3.51	26.01	3.81	-1.3	< 0.001
Mean systolic blood pressure (mm Hg)	135.93	17.43	133.43	18.18	-2.5	0.007
LDL-cholesterol (mmol/l)	4.07	1.01	4.21	1.09	0.1	0.013
Years of education	8.19	3.32	7.52	2.74	-0.7	< 0.001
Age at death, years	80.71	8.40	72.13	8.89	-8.6	< 0.001
Life years lost due to smoking	0	0	9.19	8.15	9.2	< 0.001
Age at retirement, years	56.60	5.89	55.35	6.23	-1.3	< 0.001
Years of receiving pension	23.69	9.11	16.42	9.39	-7.3	< 0.001
Number of hospitalizations	10.74	12.34	10.84	10.89	0.1	0.88
Number of inpatient days	88.47	235.25	101.55	216.23	13.1	0.28
Years of smoking (at baseline)	2.69	8.96	31.81	9.72	29.1	< 0.001
Annual income, €	34,060	22,180	27,510	17,730	-6,550	< 0.001
Occupational productivity lost due to smoking, €	0	0	34,370	27,080	34,370	< 0.001
Income taxes lost due to smoking, €	0	0	11,660	12,550	11,660	< 0.001
Annual pension, €	20,440	13,330	16,180	9,730	-4,260	< 0.001
Reduced pension costs due to smoking, €	0	0	126,850	148,120	126,850	< 0.001
Reduced income taxes paid from pensions, €	0	0	34,230	48,650	34,230	< 0.001
Annual health care costs/living individuals, €	3,420	9,870	5,040	10,650	1,620	0.003
Total health care costs, €	79,290	173,420	74,570	154,950	-4,720	0.59
Tobacco tax paid, €	2,190	8,860	50,300	32,450	48,110	< 0.001
Life years lost due to smoking, €	0	0	203,960	180,890	203,960	< 0.001
Total costs, life years lost not included, €	77,110	173,840	-56,680	195,130	-133,790	< 0.001
Total costs, life years lost included, €	77,110	173,840	147,280	195,960	70,170	< 0.001

Total costs of smoking vs. non-smoking were calculated by taking into account the life-long difference (€/person) of health care costs (€ 4,720), tobacco taxes paid (€ 48,110), income taxes lost (€ 11,660), reduced pension costs (€ 126,850), and reduced taxes paid from pensions (€ 34,230). The smoking-related harms for the society were € 11,660 + € 34,230 = € 45,890, and the smoking-related benefits for the society were € 4,720 + € 48,110 + € 126,850 = € 179,680, and thus the net effect on public finance balance was € 133,790 positive for each smoking individual. When the value of 9.19 life years lost due to smoking (€ 203,960) was taken into account, the net effect became € 70,170 negative for each smoking individual. "Income taxes lost due to smoking" indicate the loss due to earlier disability/retirement, and "Pension costs" indicate the pensions paid by the state and pension companies. The value of one quality adjusted life year lost was estimated to be $0.74 \times \text{€ } 30,000 = \text{€ } 22,200$.^{10,25}

Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



BMJ Open: first published as 10.1136/bmjopen-2012-001678 on 11 December 2012. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).



20

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	Done	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2 pp. 3,4	Explain the scientific background and rationale for the investigation being reported
Objectives	3 p. 4	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4 p. 4	Present key elements of study design early in the paper
Setting	5 p. 4	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6 pp. 4,5	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7 pp. 4,5	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8* pp.4,5	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9 Not done	Describe any efforts to address potential sources of bias
Study size	10 p. 4	Explain how the study size was arrived at
Quantitative variables	11 pp. 4,5	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12 p. 5	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed No missing data
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses

Continued on next page

Results		
Participants	13* p. 4	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage No drop-outs or missing data (c) Consider use of a flow diagram
Descriptive data	14* Done	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Table 2 (b) Indicate number of participants with missing data for each variable of interest No missing data (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) p. 4
Outcome data	15* Done	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures Tables 1 and 2
Main results	16 Done	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses No such analyses
Discussion		
Key results	18 pp. 6, 7	Summarise key results with reference to study objectives
Limitations	19 pp. 8, 9	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20 p. 9	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21 p. 9	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22 p. 11	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



**The Net Effect of Smoking on Healthcare and Welfare Costs.
A Cohort Study.**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001678.R2
Article Type:	Research
Date Submitted by the Author:	14-Nov-2012
Complete List of Authors:	Tiihonen, Jari; University of Eastern Finland, Dept of Forensic Psychiatry; Karolinska Institutet, Dept of Clinical Neuroscience Ronkainen, Kimmo; University of Eastern Finland, Institute of Public Health and Clinical Nutrition Kangasharju, Aki; Government Institute for Economic Research, Kauhanen, Jussi; University of Eastern Finland, Institute of Public Health and Clinical Nutrition
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Epidemiology, Health economics
Keywords:	EPIDEMIOLOGY, HEALTH ECONOMICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

Word count for text only: 2863 words

The Net Effect of Smoking on Healthcare and Welfare Costs. A Cohort Study.

Jari Tiihonen Professor and Chairman^{1,2,3}, Kimmo Ronkainen IT specialist⁴, Aki Kangasharju Director General⁵, Jussi Kauhanen Professor and Chairman⁴

Author Affiliations: ¹Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; ²National Institute for Health and Welfare, Helsinki, Finland; ³Departments of Psychiatry and Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital and Kuopio University Hospital, Kuopio, Finland; ⁴Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; ⁵Government Institute for Economic Research, Helsinki, Finland

Correspondence to: Prof. Jari Tiihonen, MD, PhD, Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Niuvankuja 65, FI-70240 Kuopio, Finland, tel. +358 17 203 202; fax: +358 17 203 494; jari.tiihonen@niuva.fi or jari.tiihonen@ki.se

Keywords: smoking; healthcare; costs; mortality

Submitted to BMJ Open, June 20, 2012; revised September 20, 2012, revised November 14, 2012

Abstract

Objective: To study the net economic effect of smoking on society.

Design: Prospective Cohort Study

Setting: Eastern Finland

Patients: We studied mortality, paid income and tobacco taxes, and the cumulative costs due to pensions and medical care among both tobacco smoking and non-smoking individuals in a 27-year prospective cohort study of 1,976 men from Eastern Finland. These individuals were 54–60 years old at the beginning of the follow-up.

Main Outcome Measures: The net contribution of smoking vs. non-smoking individuals to public finance balance (euros).

Results: Smoking was associated with a greater mean annual health care cost of €1,600 per living individual during follow-up. However, due to a shorter life span of 8.6 years, smokers' mean total healthcare costs during the entire study period were actually €4,700 lower than for non-smokers. For the same reason, each smoker missed 7.3 years (€126,850) of pension. Overall, smokers' average net contribution to the public finance balance was €133,800 greater per individual compared with non-smokers. However, if each lost quality adjusted life year is considered to be worth €22,200, the net effect is reversed to be €70,200 (€ 71.600 when adjusted with propensity score) per individual in favour of non-smoking.

Conclusion: Smoking was associated with a moderate decrease in health care costs, and a marked decrease in pension costs due to increased mortality. However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

Introduction

Smoking is the single most important preventable cause of premature death in industrialized countries¹, and tobacco taxation is still the most cost-effective method for decreasing the prevalence of smoking. Increases in tobacco taxes have encouraged 9 to 17% of smokers to quit^{2,3}, and in the long run the main effect of taxation is a reduction in the incidence of new young smokers.⁴ Early smoking cessation increases lifespan by about 9-10 years,⁵ and if the smoking rate diminished by 10 percentage points, life expectancy would increase by about one year. It has been estimated that a 10% increase in the price of smoked tobacco will result in about a 5% decrease in cigarette consumption,⁴ yet tobacco taxes are still low in many countries. Thus, it would be interesting to know why so many governments in the world continue to increase spending on health care costs, while a substantial savings and advances in life expectancy are readily available by administratively increasing tobacco taxes? There are two plausible explanations: the governments do not know about the correlation between increasing tobacco taxes on increasing life expectancy, or they realize this effect, but do not want to increase the life expectancy. One possible explanation is that governments are reacting to pressure from cigarette companies and smokers (either implicit or explicit) which prevents tax increases.

The net effect of smoking on healthcare costs has been investigated in several studies.⁶⁻¹⁸ Some modelling studies have suggested that while smokers suffer more from many kinds of diseases, non-smokers incur more healthcare costs because they live longer,^{6,7,8,11,12} yet others have reached the opposite conclusion.^{9,10,13-18} Only few of these studies have included both pension and insurance costs,^{7,12,17,18} and paid tobacco taxes.^{12,17,18} In 2001, Philip Morris provided a report to the Government of the Czech Republic, which indicated that the effect of smoking on the public finance balance in the Czech Republic in 1999 was positive and estimated to be 5,815 million korunas (about 150 million USD).¹² Although this report generated outraged reactions worldwide, Milos Zeman, the Czech prime minister stated "As a smoker, I support the state budget, because in the Czech Republic, we pay tax on tobacco. Also, smokers die sooner, and the state does not need to look after them in their old age".^{19,20} This report was based on many assumptions that were obtained through theoretical modelling, and it did not give any monetary value for life years lost

1
2
3 because of smoking, and it was claimed to have underestimated the costs of medical care
4 for people suffering from smoking related diseases.²¹ The overall net effect of smoking on
5 private (personal) and external costs has been studied also by Sloan et al¹⁷ and Viscusi¹⁸,
6 who used US lifetable data to model the forth-coming lifelong net costs caused by
7 smoking. As shown by van Baal et al., slightly different models can give markedly different
8 results on the net effect of smoking, depending what assumptions are used²². In any case,
9 sophisticated incidence-based datasets are ultimately required to establish the true health
10 care costs incurred by smoking.²³ Because no results have been obtained from
11 prospective, individual level data based on mortality, morbidity, pension and health care
12 costs, the net economic impact of smoking on society has remained unclear. The aim of
13 this study was to investigate this net economic effect by using data from a prospective 27-
14 year follow-up of a cohort of 1,976 Finnish middle-aged men.
15
16
17
18
19
20
21
22
23

24 Methods

25 Study population

26
27
28 The subjects of the Kuopio Ischemic Heart Disease study (KIHD) were obtained from a
29 randomly selected sample of 3,433 men, aged 42 to 60 years, who resided in the town of
30 Kuopio or its surrounding rural communities. Of those invited, 2,682 (83 %) participated in
31 the study. Of these, individuals from 54 to 60 years with complete data for smoking,
32 income, healthcare costs, retirement, and mortality (n=1,976 men) were included in the
33 final analyses. The baseline examinations were conducted between March 1984 and
34 December 1989.²⁴ The mean follow-up time was 24.2 years (range 21.1±26.8 years). The
35 KIHD study was approved by the Research Ethics Committee of the University of Kuopio,
36 in Kuopio, Finland. Each participant gave written informed consent. The end of follow-up
37 period was December 31, 2010.
38
39
40
41
42
43
44
45
46
47
48

49 A subject was defined as a smoker if he had ever smoked on a regular basis, and had
50 smoked cigarettes, cigars, or a pipe within the past 30 days. The lifelong exposure to
51 smoking ("cigarette pack-years") was estimated as the product of years smoked and the
52 number of tobacco products smoked daily at the time of examination. "Years smoked"
53 were defined as the sum of years of smoking regardless of when smoking had started,
54
55
56
57
58
59
60

1
2
3 whether the subject had stopped smoking, or whether it had occurred continuously or
4 during several periods. Data on mortality was obtained from Statistics Finland, and data on
5 healthcare costs from the Finnish Institute for Health and Welfare (THL). The health care
6 costs did not include visits to general practitioners, home nursing, or medication and dental
7 care costs in outpatient care, which have been estimated to be about 20–30% of total
8 health care costs in this age group in Finland.²⁵ The amount of paid tobacco taxes was
9 estimated on the basis of cigarette pack-years,²⁶ and the amount of paid income taxes was
10 estimated by using the income tax rate of year 1987. The amount of occupational
11 productivity and income taxes lost was calculated as the difference of age at retirement
12 (relative to the retirement age of matched non-smokers) multiplied by the annual income
13 and income tax of each smoker. “Income taxes paid” also included obligatory pension and
14 healthcare insurance fees. All monetary values were expressed as Euros (€) and
15 converted to the level of year 2009.

16
17
18 In the United Kingdom, the monetary value of one quality adjusted life year (QALY) has
19 been estimated to be 20,000–30,000 Pounds for an individual having perfect health.²⁷ In
20 the present study, we used a value of 30,000 Euros (about 25,100 Pounds in February
21 2012). In a recent large study on the effect of smoking on life expectancy, the quality-of-life
22 score among former smokers with a BMI of 25–30, who were older than 65-years was
23 estimated to be 0.71–0.77.²⁸ Therefore, we used a quality-of-life score of 0.74 for smokers
24 in the present study, thus equalling to 0.74 x 30,000 Euros = 22,200 Euros for each life
25 year lost due to smoking among former smokers aged over 65 years (deceased smokers
26 who would be over 65 if they had lived).

27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 **Statistical analysis**

44
45
46 Differences in baseline characteristics and costs were examined using the Student's t-test.
47 Descriptive data are presented as means and percentages. A p-value of less than 0.05
48 was considered statistically significant. These statistical analyses were performed using
49 SPSS 17.0 for Windows. Life expectancy for those individuals still alive on 31st December
50 2009 was calculated by using life expectancy from the Life Table provided by Statistics
51 Finland.²⁹
52
53
54
55
56
57
58
59
60

Adjusted group difference in total cost was assessed also using bootstrap type analysis of covariance (ANCOVA) with adjustments for the propensity score. Potential variables for inclusion in the propensity score (age at baseline, BMI, systolic blood pressure, LDL-cholesterol and years of education) were explored in logistic regression with a backward selection procedure ($P < 0.25$ as selection criterion). Patients were stratified based on quintiles of the propensity score. Furthermore, the fit of the propensity score model was assessed by the Hosmer–Lemeshow test.

Results

The crude mortality rates were 351/493 (71.2%) among smokers, and 553/1483 (37.3%) among non-smokers, and the cause-specific mortality in each group is shown in Table 1. The observed age at death was 67.8 years for smokers, and 71.4 years for non-smokers. The predicted mean age at death was 72.1 for smokers and 80.7 years for non-smokers, indicating 8.6 years difference between two groups. When the effect of birth year on life expectancy was taken into account, the amount of life years lost due to smoking was 9.2 years. The demographic variables and smoking-related outcomes are shown in Table 2. Smokers had substantially lower mean BMI and educational level. Smokers also had a slightly lower mean systolic blood pressure and a slightly higher mean LDL cholesterol level. Smoking was associated with a moderate decrease in productive occupational career, income taxes paid, and hospital care costs, and showed a marked decrease in pension costs. The net effect of smoking on public finance was plus € 133,800 for these smokers during the follow-up when life years lost were not included, and minus € 70,200 when a monetary value for life years lost was included in the calculation. When propensity score method was applied, the result remained almost the same (€ 71.600, 95%CI € 52.300 to € 90.800).

Figure 1 demonstrates the average annual healthcare costs as a function of age among those individuals still alive, and Figure 2 shows the corresponding results when all individuals (also deceased) are included. The higher mortality results into lower annual costs among smokers after 72 years from birth.

Discussion

Hospital care costs were 1,600 Euros greater per person year for living individuals among the smokers during the follow-up, but due to a 8.6 year shorter life span, the total costs per individual were 4,700 Euros lower among smokers than non-smokers during the entire study period. This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective, individual level data.

Smoking resulted in a moderate decrease in the productive occupational career and income taxes and pension fees paid, a moderate decrease in health care costs, and a marked decrease in the pension costs. The costs of smoking to society have been modelled by using estimates on increased mortality and morbidity.⁶⁻¹⁸ However, none of these modelling studies investigated the overall net economic effect of smoking on public finance balance by using actual data from individuals, and only few had taken into account all of the following factors; lifetime productivity or income taxes and pension fees paid, pension costs, and a monetary value of life years lost.^{17,18} Our results indicate that combined, these factors make considerable contribution to the overall net effect than merely health care costs which is in line with the modelling studies by Sloan et al.¹⁷ and Viscosi¹⁸. If the potential increase in quality adjusted life years is taken into account, our results suggest that the life long net beneficial economic effect of early smoking cessation is more than € 70,000 per individual, and this sum did not change substantially when propensity score was applied in the analysis. Our results also indicate that reducing the rate of smoking has a huge beneficial economic effect on society, mainly due to increased life span and continued pension costs. In Finland, the National Institute for Health and Welfare aims to make Finland free of smoking by the year 2040. Since there are currently about 900,000 smokers in Finland, the average net effect of € 134,000 per individual on public finance balance (without taking into account the monetary value of life years lost) would correspond during the next decades to about 120 billion Euros total increase in costs (over 2.5-fold to annual state budget). However, this nominal deficit would be massively outweighed by about 2 years increase in life expectancy of the whole nation.

Our overall results on the net economic effect of smoking on public finance balance are contrary to the Philip Morris report. A major reason for this difference is that Little did not

1
2
3 consider the inherent value of the quality adjusted life years lost. In other words, if we used
4 an estimate of 0 Euros for each lost year of human life, then the positive economic effect
5 of smoking in our study would have been even larger than the effect estimated by Little.
6
7 However, when considering the implications of these results, the major question is whether
8 or not humans are to be valued as commodities, like domesticated animals, or does human
9 life maintain an inherent value even when the individual is not longer economically
10 productive, as in retirement? In the field of health care, it is generally assumed that all
11 human life – even that of the old and disabled – is precious and has value. This view is
12 also currently accepted by national authorities throughout most of the modern world.
13 Already in 1999, 387 billion USD was used in the U.S. for medical treatment and care of
14 people older than 65 years.³⁰ Nowadays it is generally agreed that the monetary value of
15 one additional life year of a healthy human being is about 20,000-30,000 British Pounds
16 when additional costs of medical care are considered.²⁷ One may ask why societies
17 continue to invest even larger amounts of money and other social resources to achieve a
18 longer mean life span for citizens, while a more drastic increase could be achieved
19 administratively, without any further costs, by substantially raising tobacco taxes and
20 otherwise restricting access to smoking? There are two likely answers: either
21 governmental authorities have not realized this fact, or they have realized it, but do not
22 want to increase life expectancy due to a subsequent increase in both health care and
23 pension costs.
24
25
26
27
28
29
30
31
32
33
34
35

36
37
38 While denying access to medical care for older people, in order to prevent a deficit in
39 national economy, would not be possible because of common ethical concerns and public
40 opinion, preventing a decrease in smoking rates essentially has the same effect, and is
41 apparently more accepted by many societies. If this is the case, it would also explain the
42 reluctance of governments to regulate the eating and other consumption habits of that
43 negatively affect the general population by, for example, increasing the value added tax
44 (VAT) on food products that are high in sugar and saturated fats, and decreasing VAT on
45 fruits and vegetables, for example. The Czech prime minister stated in 2001 that smoking
46 is beneficial for the state, because smokers die sooner.^{17,18} Such comments have not been
47 echoed by other state leaders since, however it is plausible that this view still influences
48 tobacco policies in many modern countries. Therefore, governments should be transparent
49 concerning which kind of knowledge their tobacco and food taxation policy is based on.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Our study cannot answer the question on why cigarette taxes are still low in many
4 countries. Therefore, this remains open and a topic for further research.
5
6

7
8 The strength of this study is based on empirical data that was gathered from a 27-year
9 prospective study. Thus, no assumptions on healthcare, pension costs or discount
10 percentages of future costs were needed. One shortcoming is that this study did not
11 include females, and it did not include visits to general practitioners, home nursing, or
12 medication and dental care costs in outpatient care, which contribute to about 20–30% of
13 the total health care costs among elderly and middle aged people in Finland.²⁵ In a
14 previous 19-year follow-up study, it was observed that while the overall healthcare costs
15 were higher among smokers aged 25–59 years, the costs of medication in outpatient care
16 did not differ between smokers and non-smokers.³¹ Thus it can be further estimated that
17 the total health care costs might have been at the most about 6,000 to 7,000 Euros higher
18 per individual among non-smokers when compared with smokers, instead of our modest
19 estimate of about 5,000 Euros per individual. However, the magnitude of this difference
20 (€ 1,000–2,000) is less than 2% of the pension costs, and does not have any substantial
21 effect on these results. We also did not include the costs of fires or littering related to
22 smoking, as this information was not available, yet the combined contribution of these
23 factors is probably less than 1% of the total costs.¹² Since only 17% of the initiated
24 subjects refused to participate, the generalisability of results can be considered quite
25 sufficient.
26
27
28
29
30
31
32
33
34
35
36
37
38

39 It was presumed that smokers' lower education level and lower income level were not
40 caused by smoking, and that differences in these characteristics were associated with
41 smoking due to the fact that less educated individuals are more likely to start smoking than
42 individuals with higher educational level. Therefore, it was assumed that smoking
43 cessation would not substantially increase education level or income. It can be estimated
44 that during a productive career of about 35 years, with an annual difference of € 2,970 in
45 paid income taxes, smokers in our study have paid an average about 100,000 Euros less
46 income taxes than non-smokers. If it were assumed that early smoking cessation would
47 change these variables to the same levels as with non-smokers, the net difference
48 between smokers vs. non-smokers would shift from € 134,000 to about € 30,000 in favour
49 of smoking, if the value of life years lost are not included, and from € 70,000 to about €
50 170,000 in favour of non-smoking if the value of life years lost are included in the analysis.
51
52
53
54
55
56
57
58
59
60

1
2
3 Either way, the principal conclusions on the net costs would remain the same. It is
4 questionable if the tobacco taxes should be considered as beneficial increases in income
5 to the state. For example, if an individual would not have been smoking, then he/she
6 probably would have consumed more goods in the extra years of life and thus paid more
7 taxes for those goods instead of the taxes paid for cigarettes. Overall, the estimate of a €
8 70,000 beneficial effect of early smoking cessation per individual is probably an
9 underestimate.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

1) Article Focus

- No results have been obtained from prospective individual level data based on mortality, morbidity, pension and health care costs and, therefore, the net economic impact of smoking on society has remained unclear.

2) Key Messages

- Both the healthcare and pension costs are lower for smokers than non-smokers, the overall difference being more than 100,000 euros per individual.
- However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

3) Strengths and Limitations

- This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective data from individual subjects.
- Only males were included in study.

Funding/Support: This project was funded by the Ministry of Health and Social Affairs (Finland), the National Institute for Health and Welfare (THL) and the Academy of Finland. The funders were not involved in the conduct of the study, or in the collection, management, analysis or interpretation of the data.

Competing Interest: All authors have completed the Unified Competing Interest form at www.icmj.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: Dr Tiihonen is a member of advisory board of AstraZeneca and Janssen-Cilag, and he reports serving as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, and lecture fees from Janssen-Cilag, Bristol Myers-Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, Novartis, and Astra Zeneca. No further disclosures were reported.

Contributors: JT, KR and JK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JT wrote the first draft of the manuscript and all other authors read and had input in the final version of the paper. JT did study concept and design, KR and JK collected data, KR did statistical analysis and KR produced figures. JT is the guarantor.

Ethical approval: The KIHD study was approved by the Research Ethics Committee of the University of Kuopio, in Kuopio, Finland.

Data sharing: No additional data available.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).

References

- 1 Schroeder SA, Warner KE. Don't forget tobacco. *N Engl J Med* 2010;363:201-4.
- 2 Dunlop SM, Cotter TF, Perez DA. Impact of the 2010 tobacco tax increase in Australia on short-term smoking cessation: a continuous tracking survey. *Med J Aust* 2011;195:469-72.
- 3 Choi TC, Toomey TL, Chen V, *et al.* Awareness and reported consequences of a cigarette tax increase among older adolescents and young adults. *Am J Health Promot* 2011;25:379-86.
- 4 Gallet CA, List JA. Cigarette demand: a meta-analysis of elasticities. *Health Economics* 2003;12:821-35.
- 5 Doll R, Peto R, Boreham J, *et al.* Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
- 6 Leu RE, Schaub T. Does smoking increase medical care expenditure? *Soc Sci Med* 1983;17:1907-14.
- 7 Manning WG, Keeler EB, Newhouse JP, *et al.* The taxes of sin. Do smokers and drinkers pay their way? *JAMA* 1989;261:1604-9.
- 8 Lippiatt BC. Measuring medical cost and life expectancy impacts of changes in cigarette sales. *Prev Med* 1990;19:515-32.
- 9 MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco use. *N Engl J Med* 1994;330:975-80.
- 10 Smoking-related deaths and financial costs: estimates for 1990. Rev. ed. Washington, DC: Office of Technology Assessment, 1993.
- 11 Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. *N Engl J Med* 1997;337:1052-7.
- 12 Arthur D. Little International, Inc. Philip Morris funded study of smoking in the Czech Republic stating that the Czech government had a net gain of \$147.1 million from smoking. <http://www.mindfully.org/Industry/Philip-Morris-Czech-Study.htm>. Accessed November 21, 2011.
- 13 Yang L, Sung HY, Mao Z, *et al.* Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. *Tob Control* 2011;20:266-72.

- 1
2
3 14 Callum C, Boyle S, Sandford A. Estimating the cost of smoking to the NHS in
4 England and the impact of declining prevalence. *Health Econ Policy Law* 2011;6:489-
5 508.
6
7
8 15 Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. *Soc*
9 *Sci Med* 1999;48:375-91.
10
11 16 Miller LS, Max W, Sung HY, *et al.* Evaluation of the economic impact of California's
12 Tobacco Control Program: a dynamic model approach. *Tob Control* 2010;19(Suppl
13 1):i68-i76.
14
15
16 17 Sloan FA, Ostermann J, Picone G, Conover C, Taylor DH Jr. The Price of Smoking.
17 The MIT Press: Cambridge, Massachusetts, London, England 2004.
18
19 18 Viscusi WK. The Governmental Composition of the Insurance Costs of Smoking. *J*
20 *Law Economics* 1999 ;42 :574-609
21
22 19 L'Organisation mondiale de la Santé. Guide pour la mise en place de l'action
23 antitabac. 2006, p. 21.
24
25 20 Holley David (August 05, 2001): "Philip Morris Angers Czechs With Tobacco Toll
26 Report – Los Angeles Times" ([http://articles.latimes.com/2001/aug/05/news/mn-](http://articles.latimes.com/2001/aug/05/news/mn-30831)
27 30831). Los Angeles Times. Accessed December 12, 2011.
28
29 21 <http://www.tobacco.org/news/70612.html>. Accessed December 23, 2011.
30
31 22 van Baal PH, Feenstra TL, Polder JJ, *et al.* Economic evaluation and the
32 postponement of health care costs. *Health Econ* 2011;20:432-45.
33
34 23 Heaney D. The health care costs of smoking. *N Engl J Med* 1998;338:471; author
35 reply 472.
36
37 24 Lakka TA, Venäläinen JM, Rauramaa R, *et al.* Relation of leisure-time physical
38 activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men.
39 *N Engl J Med* 1994;330:1549-54.
40
41 25 Kuntaliitto. Suurten kaupunkien terveydenhuollon kustannukset vuonna 2010.
42 Helsinki: Suomen kuntaliitto, 2011.
43
44 26 Official Statistics of Finland. Tobacco Statistics 2009. Helsinki: Statistics Finland,
45 2010.
46
47 27 National Institute for Health and Clinical Excellence. Measuring effectiveness and
48 cost effectiveness: the QALY.
49 [http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivene](http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp)
50 [sstheqaly.jsp](http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp). Accessed December 12, 2011.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28 Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on
4 U.S. life expectancy. *N Engl J Med* 2009;361:2252-60.
5
6 29 Statistics Finland. Life Table 2007/Life expectancy of men, by age. Statistics Finland.
7 <http://www.staft.fi/til/kuol/tau.html>. Accessed February 9, 2012.
8
9 30 Keehan SP, Lazenby HC, Zezza MA, et al. Age Estimates in the National Health
10 Accounts. *Health Care Financing Review* 2004 Dec. 2; 1(1); Web Exclusive.
11
12 31 Kiiskinen U, Vartiainen E, Puska P, et al. Smoking-related costs among 25 to 59
13 year-old males in a 19-year individual follow-up. *Eur J Publ Health* 2002;12:145-51.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Cause-specific mortality among smokers and non-smokers.

Cause of death	Non-smokers (%)	Smokers (%)
Cardiovascular disease	267 (48%)	166 (47%)
Cancer (all)	146 (26%)	102 (29%)
Lung cancer	15 (3%)	47 (13%)
Respiratory disease	13 (2%)	20 (6%)
External causes of death	56 (10%)	28 (8%)
Other	71 (13%)	35 (10%)
Total	553 (100%)	351 (100%)

A total of 553 (37.3%) non-smokers and 351 (71.2%) smokers had died during the follow-up. Percentages indicate the proportions for cause of death from all deaths in each group. Cancer deaths include lung cancer deaths.

Table 2. Smoking-related outcomes.

	Non-smokers N=1483		Smokers N=493		Difference of means	p-value
	Mean	S.D.	Mean	S.D.		
Age at baseline, years	55.72	2.50	55.54	2.38	-0.2	0.17
Body mass index (BMI)	27.29	3.51	26.01	3.81	-1.3	< 0.001
Mean systolic blood pressure (mm Hg)	135.93	17.43	133.43	18.18	-2.5	0.007
LDL-cholesterol (mmol/l)	4.07	1.01	4.21	1.09	0.1	0.013
Years of education	8.19	3.32	7.52	2.74	-0.7	< 0.001
Age at death, years	80.71	8.40	72.13	8.89	-8.6	< 0.001
Life years lost due to smoking	0	0	9.19	8.15	9.2	< 0.001
Age at retirement, years	56.60	5.89	55.35	6.23	-1.3	< 0.001
Years of receiving pension	23.69	9.11	16.42	9.39	-7.3	< 0.001
Number of hospitalizations	10.74	12.34	10.84	10.89	0.1	0.88
Number of inpatient days	88.47	235.25	101.55	216.23	13.1	0.28
Years of smoking (at baseline)	2.69	8.96	31.81	9.72	29.1	< 0.001
Annual income, €	34,060	22,180	27,510	17,730	-6,550	< 0.001
Occupational productivity lost due to smoking, €	0	0	34,370	27,080	34,370	< 0.001
Income taxes lost due to smoking, €	0	0	11,660	12,550	11,660	< 0.001
Annual pension, €	20,440	13,330	16,180	9,730	-4,260	< 0.001
Reduced pension costs due to smoking, €	0	0	126,850	148,120	126,850	< 0.001
Reduced income taxes paid from pensions, €	0	0	34,230	48,650	34,230	< 0.001
Annual health care costs/living individuals, €	3,420	9,870	5,040	10,650	1,620	0.003
Total health care costs, €	79,290	173,420	74,570	154,950	-4,720	0.59
Tobacco tax paid, €	2,190	8,860	50,300	32,450	48,110	< 0.001
Life years lost due to smoking, €	0	0	203,960	180,890	203,960	< 0.001
Total costs, life years lost not included, €	77,110	173,840	-56,680	195,130	-133,790	< 0.001
Total costs, life years lost included, €	77,110	173,840	147,280	195,960	70,170	< 0.001

Total costs of smoking vs. non-smoking were calculated by taking into account the life-long difference (€/person) of health care costs (€ 4,720), tobacco taxes paid (€ 48,110), income taxes lost (€ 11,660), reduced pension costs (€ 126,850), and reduced taxes paid from pensions (€ 34,230). The smoking-related harms for the society were € 11,660 + € 34,230 = € 45,890, and the smoking-related benefits for the society were € 4,720 + € 48,110 + € 126,850 = € 179,680, and thus the net effect on public finance balance was € 133,790 positive for each smoking individual. When the value of 9.19 life years lost due to smoking (€ 203,960) was taken into account, the net effect became € 70,170 negative for each smoking individual. "Income taxes lost due to smoking" indicate the loss due to earlier disability/retirement, and "Pension costs" indicate the pensions paid by the state and pension companies. The value of one quality adjusted life year lost was estimated to be $0.74 \times € 30,000 = € 22,200$.^{10,25}

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Word count for text only: 2863 words

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The Net Effect of Smoking on and Healthcare and Welfare Costs. A Cohort Study.

Jari Tiihonen Professor and Chairman^{1,2,3}, Kimmo Ronkainen IT specialist⁴, Aki Kangasharju Director General⁵, Jussi Kauhanen Professor and Chairman⁴

Author Affiliations: ¹Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; ²National Institute for Health and Welfare, Helsinki, Finland; ³Departments of Psychiatry and Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital and Kuopio University Hospital, Kuopio, Finland; ⁴Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; ⁵Government Institute for Economic Research, Helsinki, Finland

Correspondence to: Prof. Jari Tiihonen, MD, PhD, Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Niuvankuja 65, FI-70240 Kuopio, Finland, tel. +358 17 203 202; fax: +358 17 203 494; jari.tiihonen@niuva.fi or jari.tiihonen@ki.se

Keywords: smoking; healthcare; costs; mortality

Submitted to BMJ Open, June 20, 2012; revised September 20, 2012, revised November 14, 2012

Abstract

Objective: To study the net economic effect of smoking on society.

Design, Setting, and Patients: We studied mortality, paid income and tobacco taxes, and the cumulative costs due to pensions and medical care among both tobacco smoking and non-smoking individuals in a 27-year prospective cohort study of 1,976 men from Eastern Finland. These individuals were 54–60 years old at the beginning of the follow-up.

Main Outcome Measures: The net contribution of smoking vs. non-smoking individuals to public finance balance (euros).

Results: Smoking was associated with a greater mean annual health care cost of €1,600 per living individual during follow-up. However, due to a shorter life span of 8.6 years, smokers' mean total healthcare costs during the entire study period were actually €4,700 lower than for non-smokers. For the same reason, each smoker missed 7.3 years (€126,850) of pension. Overall, smokers' average net contribution to the public finance balance was €133,800 greater per individual compared with non-smokers. However, if each lost quality adjusted life year is considered to be worth €22,200, the net effect is reversed to be €70,200 (€ 71.600 when adjusted with propensity score) per individual in favour of non-smoking.

Conclusion: Smoking was associated with a moderate decrease in health care costs, and a marked decrease in pension costs due to increased mortality. However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

Introduction

Smoking is the single most important preventable cause of premature death in industrialized countries¹, and tobacco taxation is still the most cost-effective method for decreasing the prevalence of smoking. Increases in tobacco taxes have encouraged 9 to 17% of smokers to quit^{2,3}, and in the long run the main effect of taxation is a reduction in the incidence of new young smokers.⁴ Early smoking cessation increases lifespan by about 9-10 years,⁵ and if the smoking rate diminished by 10 percentage points, life expectancy would increase by about one year. It has been estimated that a 10% increase in the price of smoked tobacco will result in about a 5% decrease in cigarette consumption,⁴ yet tobacco taxes are still low in many countries. Thus, it would be interesting to know why so many governments in the world continue to increase spending on health care costs, while a substantial savings and advances in life expectancy are readily available by administratively increasing tobacco taxes? There are two plausible explanations: the governments do not know about the correlation between increasing tobacco taxes on increasing life expectancy, or they realize this effect, but do not want to increase the life expectancy. One possible explanation is that governments are reacting to pressure from cigarette companies and smokers (either implicit or explicit) which prevents tax increases.

The net effect of smoking on healthcare costs has been investigated in several studies.⁶⁻¹⁸ Some modelling studies have suggested that while smokers suffer more from many kinds of diseases, non-smokers incur more healthcare costs because they live longer,^{6,7,8,11,12} yet others have reached the opposite conclusion.^{9,10,13-18} Only few of these studies have included both pension and insurance costs,^{7,12,17,18} and paid tobacco taxes.^{12,17,18} In 2001, Philip Morris provided a report to the Government of the Czech Republic, which indicated that the effect of smoking on the public finance balance in the Czech Republic in 1999 was positive and estimated to be 5,815 million korunas (about 150 million USD).¹² Although this report generated outraged reactions worldwide, Milos Zeman, the Czech prime minister stated "As a smoker, I support the state budget, because in the Czech Republic, we pay tax on tobacco. Also, smokers die sooner, and the state does not need to look after them in their old age".^{19,20} This report was based on many assumptions that were obtained through theoretical modelling, and it did not give any monetary value for life years lost

1
2
3 because of smoking, and it was claimed to have underestimated the costs of medical care
4 for people suffering from smoking related diseases.²¹ The overall net effect of smoking on
5 private (personal) and external costs has been studied also by Sloan et al¹⁷ and Viscusi¹⁸,
6 who used US lifetable data to model the forth-coming lifelong net costs caused by
7 smoking. As shown by van Baal et al., slightly different models can give markedly different
8 results on the net effect of smoking, depending what assumptions are used²². In any case,
9 sophisticated incidence-based datasets are ultimately required to establish the true health
10 care costs incurred by smoking.²³ Because no results have been obtained from
11 prospective, individual level data based on mortality, morbidity, pension and health care
12 costs, the net economic impact of smoking on society has remained unclear. The aim of
13 this study was to investigate this net economic effect by using data from a prospective 27-
14 year follow-up of a cohort of 1,976 Finnish middle-aged men.
15
16
17
18
19
20
21
22
23

24 Methods

25 Study population

26
27
28 The subjects of the Kuopio Ischemic Heart Disease study (KIHD) were obtained from a
29 randomly selected sample of 3,433 men, aged 42 to 60 years, who resided in the town of
30 Kuopio or its surrounding rural communities. Of those invited, 2,682 (83 %) participated in
31 the study. Of these, individuals from 54 to 60 years with complete data for smoking,
32 income, healthcare costs, retirement, and mortality (n=1,976 men) were included in the
33 final analyses. The baseline examinations were conducted between March 1984 and
34 December 1989.²⁴ The mean follow-up time was 24.2 years (range 21.1±26.8 years). The
35 KIHD study was approved by the Research Ethics Committee of the University of Kuopio,
36 in Kuopio, Finland. Each participant gave written informed consent. The end of follow-up
37 period was December 31, 2010.
38
39
40
41
42
43
44
45
46
47
48

49 A subject was defined as a smoker if he had ever smoked on a regular basis, and had
50 smoked cigarettes, cigars, or a pipe within the past 30 days. The lifelong exposure to
51 smoking ("cigarette pack-years") was estimated as the product of years smoked and the
52 number of tobacco products smoked daily at the time of examination. "Years smoked"
53 were defined as the sum of years of smoking regardless of when smoking had started,
54
55
56
57
58
59
60

1
2
3 whether the subject had stopped smoking, or whether it had occurred continuously or
4 during several periods. Data on mortality was obtained from Statistics Finland, and data on
5 healthcare costs from the Finnish Institute for Health and Welfare (THL). The health care
6 costs did not include visits to general practitioners, home nursing, or medication and dental
7 care costs in outpatient care, which have been estimated to be about 20–30% of total
8 health care costs in this age group in Finland.²⁵ The amount of paid tobacco taxes was
9 estimated on the basis of cigarette pack-years,²⁶ and the amount of paid income taxes was
10 estimated by using the income tax rate of year 1987. The amount of occupational
11 productivity and income taxes lost was calculated as the difference of age at retirement
12 (relative to the retirement age of matched non-smokers) multiplied by the annual income
13 and income tax of each smoker. “Income taxes paid” also included obligatory pension and
14 healthcare insurance fees. All monetary values were expressed as Euros (€) and
15 converted to the level of year 2009.

16
17
18 In the United Kingdom, the monetary value of one quality adjusted life year (QALY) has
19 been estimated to be 20,000–30,000 Pounds for an individual having perfect health.²⁷ In
20 the present study, we used a value of 30,000 Euros (about 25,100 Pounds in February
21 2012). In a recent large study on the effect of smoking on life expectancy, the quality-of-life
22 score among former smokers with a BMI of 25–30, who were older than 65-years was
23 estimated to be 0.71–0.77.²⁸ Therefore, we used a quality-of-life score of 0.74 for smokers
24 in the present study, thus equalling to 0.74 x 30,000 Euros = 22,200 Euros for each life
25 year lost due to smoking among former smokers aged over 65 years (deceased smokers
26 who would be over 65 if they had lived).

27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 **Statistical analysis**

44
45
46 Differences in baseline characteristics and costs were examined using the Student's t-test.
47 Descriptive data are presented as means and percentages. A p-value of less than 0.05
48 was considered statistically significant. These statistical analyses were performed using
49 SPSS 17.0 for Windows. Life expectancy for those individuals still alive on 31st December
50 2009 was calculated by using life expectancy from the Life Table provided by Statistics
51 Finland.²⁹
52
53
54
55
56
57
58
59
60

Adjusted group difference in total cost was assessed also using bootstrap type analysis of covariance (ANCOVA) with adjustments for the propensity score. Potential variables for inclusion in the propensity score (age at baseline, BMI, systolic blood pressure, LDL-cholesterol and years of education) were explored in logistic regression with a backward selection procedure ($P < 0.25$ as selection criterion). Patients were stratified based on quintiles of the propensity score. Furthermore, the fit of the propensity score model was assessed by the Hosmer–Lemeshow test.

Results

The crude mortality rates were 351/493 (71.2%) among smokers, and 553/1483 (37.3%) among non-smokers, and the cause-specific mortality in each group is shown in Table 1. The observed age at death was 67.8 years for smokers, and 71.4 years for non-smokers. The predicted mean age at death was 72.1 for smokers and 80.7 years for non-smokers, indicating 8.6 years difference between two groups. When the effect of birth year on life expectancy was taken into account, the amount of life years lost due to smoking was 9.2 years. The demographic variables and smoking-related outcomes are shown in Table 2. Smokers had substantially lower mean BMI and educational level. Smokers also had a slightly lower mean systolic blood pressure and a slightly higher mean LDL cholesterol level. Smoking was associated with a moderate decrease in productive occupational career, income taxes paid, and hospital care costs, and showed a marked decrease in pension costs. The net effect of smoking on public finance was plus € 133,800 for these smokers during the follow-up when life years lost were not included, and minus € 70,200 when a monetary value for life years lost was included in the calculation. When propensity score method was applied, the result remained almost the same (€ 71.600, 95%CI € 52.300 to € 90.800).

Figure 1 demonstrates the average annual healthcare costs as a function of age among those individuals still alive, and Figure 2 shows the corresponding results when all individuals (also deceased) are included. The higher mortality results into lower annual costs among smokers after 72 years from birth.

Discussion

Hospital care costs were 1,600 Euros greater per person year for living individuals among the smokers during the follow-up, but due to a 8.6 year shorter life span, the total costs per individual were 4,700 Euros lower among smokers than non-smokers during the entire study period. This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective, individual level data.

Smoking resulted in a moderate decrease in the productive occupational career and income taxes and pension fees paid, a moderate decrease in health care costs, and a marked decrease in the pension costs. The costs of smoking to society have been modelled by using estimates on increased mortality and morbidity.⁶⁻¹⁸ However, none of these modelling studies investigated the overall net economic effect of smoking on public finance balance by using actual data from individuals, and only few had taken into account all of the following factors; lifetime productivity or income taxes and pension fees paid, pension costs, and a monetary value of life years lost.^{17,18} Our results indicate that combined, these factors make considerable contribution to the overall net effect than merely health care costs which is in line with the modelling studies by Sloan et al.¹⁷ and Viscosi¹⁸. If the potential increase in quality adjusted life years is taken into account, our results suggest that the life long net beneficial economic effect of early smoking cessation is more than € 70,000 per individual, and this sum did not change substantially when propensity score was applied in the analysis. Our results also indicate that reducing the rate of smoking has a huge beneficial economic effect on society, mainly due to increased life span and continued pension costs. In Finland, the National Institute for Health and Welfare aims to make Finland free of smoking by the year 2040. Since there are currently about 900,000 smokers in Finland, the average net effect of € 134,000 per individual on public finance balance (without taking into account the monetary value of life years lost) would correspond during the next decades to about 120 billion Euros total increase in costs (over 2.5-fold to annual state budget). However, this nominal deficit would be massively outweighed by about 2 years increase in life expectancy of the whole nation.

Our overall results on the net economic effect of smoking on public finance balance are contrary to the Philip Morris report. A major reason for this difference is that Little did not

1
2
3 consider the inherent value of the quality adjusted life years lost. In other words, if we used
4 an estimate of 0 Euros for each lost year of human life, then the positive economic effect
5 of smoking in our study would have been even larger than the effect estimated by Little.
6
7 However, when considering the implications of these results, the major question is whether
8 or not humans are to be valued as commodities, like domesticated animals, or does human
9 life maintain an inherent value even when the individual is not longer economically
10 productive, as in retirement? In the field of health care, it is generally assumed that all
11 human life – even that of the old and disabled – is precious and has value. This view is
12 also currently accepted by national authorities throughout most of the modern world.
13
14 Already in 1999, 387 billion USD was used in the U.S. for medical treatment and care of
15 people older than 65 years.³⁰ Nowadays it is generally agreed that the monetary value of
16 one additional life year of a healthy human being is about 20,000-30,000 British Pounds
17 when additional costs of medical care are considered.²⁷ One may ask why societies
18 continue to invest even larger amounts of money and other social resources to achieve a
19 longer mean life span for citizens, while a more drastic increase could be achieved
20 administratively, without any further costs, by substantially raising tobacco taxes and
21 otherwise restricting access to smoking? There are two likely answers: either
22 governmental authorities have not realized this fact, or they have realized it, but do not
23 want to increase life expectancy due to a subsequent increase in both health care and
24 pension costs.
25
26
27
28
29
30
31
32
33
34
35
36
37

38 While denying access to medical care for older people, in order to prevent a deficit in
39 national economy, would not be possible because of common ethical concerns and public
40 opinion, preventing a decrease in smoking rates essentially has the same effect, and is
41 apparently more accepted by many societies. If this is the case, it would also explain the
42 reluctance of governments to regulate the eating and other consumption habits of that
43 negatively affect the general population by, for example, increasing the value added tax
44 (VAT) on food products that are high in sugar and saturated fats, and decreasing VAT on
45 fruits and vegetables, for example. The Czech prime minister stated in 2001 that smoking
46 is beneficial for the state, because smokers die sooner.^{17,18} Such comments have not been
47 echoed by other state leaders since, however it is plausible that this view still influences
48 tobacco policies in many modern countries. Therefore, governments should be transparent
49 concerning which kind of knowledge their tobacco and food taxation policy is based on.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Our study cannot answer the question on why cigarette taxes are still low in many
4 countries. Therefore, this remains open and a topic for further research.
5
6

7
8 The strength of this study is based on empirical data that was gathered from a 27-year
9 prospective study. Thus, no assumptions on healthcare, pension costs or discount
10 percentages of future costs were needed. One shortcoming is that this study did not
11 include females, and it did not include visits to general practitioners, home nursing, or
12 medication and dental care costs in outpatient care, which contribute to about 20–30% of
13 the total health care costs among elderly and middle aged people in Finland.²⁵ In a
14 previous 19-year follow-up study, it was observed that while the overall healthcare costs
15 were higher among smokers aged 25–59 years, the costs of medication in outpatient care
16 did not differ between smokers and non-smokers.³¹ Thus it can be further estimated that
17 the total health care costs might have been at the most about 6,000 to 7,000 Euros higher
18 per individual among non-smokers when compared with smokers, instead of our modest
19 estimate of about 5,000 Euros per individual. However, the magnitude of this difference
20 (€ 1,000–2,000) is less than 2% of the pension costs, and does not have any substantial
21 effect on these results. We also did not include the costs of fires or littering related to
22 smoking, as this information was not available, yet the combined contribution of these
23 factors is probably less than 1% of the total costs.¹² Since only 17% of the initiated
24 subjects refused to participate, the generalisability of results can be considered quite
25 sufficient.
26
27
28
29
30
31
32
33
34
35
36
37
38

39 It was presumed that smokers' lower education level and lower income level were not
40 caused by smoking, and that differences in these characteristics were associated with
41 smoking due to the fact that less educated individuals are more likely to start smoking than
42 individuals with higher educational level. Therefore, it was assumed that smoking
43 cessation would not substantially increase education level or income. It can be estimated
44 that during a productive career of about 35 years, with an annual difference of € 2,970 in
45 paid income taxes, smokers in our study have paid an average about 100,000 Euros less
46 income taxes than non-smokers. If it were assumed that early smoking cessation would
47 change these variables to the same levels as with non-smokers, the net difference
48 between smokers vs. non-smokers would shift from € 134,000 to about € 30,000 in favour
49 of smoking, if the value of life years lost are not included, and from € 70,000 to about €
50 170,000 in favour of non-smoking if the value of life years lost are included in the analysis.
51
52
53
54
55
56
57
58
59
60

1
2
3 Either way, the principal conclusions on the net costs would remain the same. It is
4 questionable if the tobacco taxes should be considered as beneficial increases in income
5 to the state. For example, if an individual would not have been smoking, then he/she
6 probably would have consumed more goods in the extra years of life and thus paid more
7 taxes for those goods instead of the taxes paid for cigarettes. Overall, the estimate of a €
8 70,000 beneficial effect of early smoking cessation per individual is probably an
9 underestimate.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

1) Article Focus

- No results have been obtained from prospective individual level data based on mortality, morbidity, pension and health care costs and, therefore, the net economic impact of smoking on society has remained unclear.

2) Key Messages

- Both the healthcare and pension costs are lower for smokers than non-smokers, the overall difference being more than 100,000 euros per individual.
- However, when a monetary value for life years lost was taken into account, the beneficial net effect of non-smoking to society was about €70,000 per individual.

3) Strengths and Limitations

- This study provides the first evidence for the net economic effect of smoking vs. non-smoking on costs related to health and social welfare, based on prospective data from individual subjects.
- Only males were included in study.

Funding/Support: This project was funded by the Ministry of Health and Social Affairs (Finland), the National Institute for Health and Welfare (THL) and the Academy of Finland. The funders were not involved in the conduct of the study, or in the collection, management, analysis or interpretation of the data.

Competing Interest: All authors have completed the Unified Competing Interest form at www.icmj.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: Dr Tiihonen is a member of advisory board of AstraZeneca and Janssen-Cilag, and he reports serving as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, and lecture fees from Janssen-Cilag, Bristol Myers-Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, Novartis, and Astra Zeneca. No further disclosures were reported.

Contributors: JT, KR and JK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JT wrote the first draft of the manuscript and all other authors read and had input in the final version of the paper. JT did study concept and design, KR and JK collected data, KR did statistical analysis and KR produced figures. JT is the guarantor.

Ethical approval: The KIHD study was approved by the Research Ethics Committee of the University of Kuopio, in Kuopio, Finland.

Data sharing: No additional data available.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).

References

- 1 Schroeder SA, Warner KE. Don't forget tobacco. *N Engl J Med* 2010;363:201-4.
- 2 Dunlop SM, Cotter TF, Perez DA. Impact of the 2010 tobacco tax increase in Australia on short-term smoking cessation: a continuous tracking survey. *Med J Aust* 2011;195:469-72.
- 3 Choi TC, Toomey TL, Chen V, *et al.* Awareness and reported consequences of a cigarette tax increase among older adolescents and young adults. *Am J Health Promot* 2011;25:379-86.
- 4 Gallet CA, List JA. Cigarette demand: a meta-analysis of elasticities. *Health Economics* 2003;12:821-35.
- 5 Doll R, Peto R, Boreham J, *et al.* Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
- 6 Leu RE, Schaub T. Does smoking increase medical care expenditure? *Soc Sci Med* 1983;17:1907-14.
- 7 Manning WG, Keeler EB, Newhouse JP, *et al.* The taxes of sin. Do smokers and drinkers pay their way? *JAMA* 1989;261:1604-9.
- 8 Lippiatt BC. Measuring medical cost and life expectancy impacts of changes in cigarette sales. *Prev Med* 1990;19:515-32.
- 9 MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco use. *N Engl J Med* 1994;330:975-80.
- 10 Smoking-related deaths and financial costs: estimates for 1990. Rev. ed. Washington, DC: Office of Technology Assessment, 1993.
- 11 Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. *N Engl J Med* 1997;337:1052-7.
- 12 Arthur D. Little International, Inc. Philip Morris funded study of smoking in the Czech Republic stating that the Czech government had a net gain of \$147.1 million from smoking. <http://www.mindfully.org/Industry/Philip-Morris-Czech-Study.htm>. Accessed November 21, 2011.
- 13 Yang L, Sung HY, Mao Z, *et al.* Economic costs attributable to smoking in China: update and an 8-year comparison, 2000-2008. *Tob Control* 2011;20:266-72.

- 1
2
3 14 Callum C, Boyle S, Sandford A. Estimating the cost of smoking to the NHS in
4 England and the impact of declining prevalence. *Health Econ Policy Law* 2011;6:489-
5 508.
6
7
8 15 Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. *Soc*
9 *Sci Med* 1999;48:375-91.
10
11 16 Miller LS, Max W, Sung HY, *et al.* Evaluation of the economic impact of California's
12 Tobacco Control Program: a dynamic model approach. *Tob Control* 2010;19(Suppl
13 1):i68-i76.
14
15
16 17 Sloan FA, Ostermann J, Picone G, Conover C, Taylor DH Jr. The Price of Smoking.
17 The MIT Press: Cambridge, Massachusetts, London, England 2004.
18
19 18 Viscusi WK. The Governmental Composition of the Insurance Costs of Smoking. *J*
20 *Law Economics* 1999 ;42 :574-609
21
22 19 L'Organisation mondiale de la Santé. Guide pour la mise en place de l'action
23 antitabac. 2006, p. 21.
24
25 20 Holley David (August 05, 2001): "Philip Morris Angers Czechs With Tobacco Toll
26 Report – Los Angeles Times" ([http://articles.latimes.com/2001/aug/05/news/mn-](http://articles.latimes.com/2001/aug/05/news/mn-30831)
27 30831). Los Angeles Times. Accessed December 12, 2011.
28
29 21 <http://www.tobacco.org/news/70612.html>. Accessed December 23, 2011.
30
31 22 van Baal PH, Feenstra TL, Polder JJ, *et al.* Economic evaluation and the
32 postponement of health care costs. *Health Econ* 2011;20:432-45.
33
34 23 Heaney D. The health care costs of smoking. *N Engl J Med* 1998;338:471; author
35 reply 472.
36
37 24 Lakka TA, Venäläinen JM, Rauramaa R, *et al.* Relation of leisure-time physical
38 activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men.
39 *N Engl J Med* 1994;330:1549-54.
40
41 25 Kuntaliitto. Suurten kaupunkien terveydenhuollon kustannukset vuonna 2010.
42 Helsinki: Suomen kuntaliitto, 2011.
43
44 26 Official Statistics of Finland. Tobacco Statistics 2009. Helsinki: Statistics Finland,
45 2010.
46
47 27 National Institute for Health and Clinical Excellence. Measuring effectiveness and
48 cost effectiveness: the QALY.
49 <http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenessstheqaly.jsp>. Accessed December 12, 2011.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28 Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on
4 U.S. life expectancy. *N Engl J Med* 2009;361:2252-60.
5
6 29 Statistics Finland. Life Table 2007/Life expectancy of men, by age. Statistics Finland.
7 <http://www.staft.fi/til/kuol/tau.html>. Accessed February 9, 2012.
8
9 30 Keehan SP, Lazenby HC, Zezza MA, et al. Age Estimates in the National Health
10 Accounts. *Health Care Financing Review* 2004 Dec. 2; 1(1); Web Exclusive.
11
12 31 Kiiskinen U, Vartiainen E, Puska P, et al. Smoking-related costs among 25 to 59
13 year-old males in a 19-year individual follow-up. *Eur J Publ Health* 2002;12:145-51.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).

For peer review only

Table 1. Cause-specific mortality among smokers and non-smokers.

Cause of death	Non-smokers (%)	Smokers (%)
Cardiovascular disease	267 (48%)	166 (47%)
Cancer (all)	146 (26%)	102 (29%)
Lung cancer	15 (3%)	47 (13%)
Respiratory disease	13 (2%)	20 (6%)
External causes of death	56 (10%)	28 (8%)
Other	71 (13%)	35 (10%)
Total	553 (100%)	351 (100%)


A total of 553 (37.3%) non-smokers and 351 (71.2%) smokers had died during the follow-up. Percentages indicate the proportions for cause of death from all deaths in each group. Cancer deaths include lung cancer deaths.

Table 2. Smoking-related outcomes.

	Non-smokers N=1483		Smokers N=493		Difference of means	p-value
	Mean	S.D.	Mean	S.D.		
Age at baseline, years	55.72	2.50	55.54	2.38	-0.2	0.17
Body mass index (BMI)	27.29	3.51	26.01	3.81	-1.3	< 0.001
Mean systolic blood pressure (mm Hg)	135.93	17.43	133.43	18.18	-2.5	0.007
LDL-cholesterol (mmol/l)	4.07	1.01	4.21	1.09	0.1	0.013
Years of education	8.19	3.32	7.52	2.74	-0.7	< 0.001
Age at death, years	80.71	8.40	72.13	8.89	-8.6	< 0.001
Life years lost due to smoking	0	0	9.19	8.15	9.2	< 0.001
Age at retirement, years	56.60	5.89	55.35	6.23	-1.3	< 0.001
Years of receiving pension	23.69	9.11	16.42	9.39	-7.3	< 0.001
Number of hospitalizations	10.74	12.34	10.84	10.89	0.1	0.88
Number of inpatient days	88.47	235.25	101.55	216.23	13.1	0.28
Years of smoking (at baseline)	2.69	8.96	31.81	9.72	29.1	< 0.001
Annual income, €	34,060	22,180	27,510	17,730	-6,550	< 0.001
Occupational productivity lost due to smoking, €	0	0	34,370	27,080	34,370	< 0.001
Income taxes lost due to smoking, €	0	0	11,660	12,550	11,660	< 0.001
Annual pension, €	20,440	13,330	16,180	9,730	-4,260	< 0.001
Reduced pension costs due to smoking, €	0	0	126,850	148,120	126,850	< 0.001
Reduced income taxes paid from pensions, €	0	0	34,230	48,650	34,230	< 0.001
Annual health care costs/living individuals, €	3,420	9,870	5,040	10,650	1,620	0.003
Total health care costs, €	79,290	173,420	74,570	154,950	-4,720	0.59
Tobacco tax paid, €	2,190	8,860	50,300	32,450	48,110	< 0.001
Life years lost due to smoking, €	0	0	203,960	180,890	203,960	< 0.001
Total costs, life years lost not included, €	77,110	173,840	-56,680	195,130	-133,790	< 0.001
Total costs, life years lost included, €	77,110	173,840	147,280	195,960	70,170	< 0.001

Total costs of smoking vs. non-smoking were calculated by taking into account the life-long difference (€/person) of health care costs (€ 4,720), tobacco taxes paid (€ 48,110), income taxes lost (€ 11,660), reduced pension costs (€ 126,850), and reduced taxes paid from pensions (€ 34,230). The smoking-related harms for the society were € 11,660 + € 34,230 = € 45,890, and the smoking-related benefits for the society were € 4,720 + € 48,110 + € 126,850 = € 179,680, and thus the net effect on public finance balance was € 133,790 positive for each smoking individual. When the value of 9.19 life years lost due to smoking (€ 203,960) was taken into account, the net effect became € 70,170 negative for each smoking individual. "Income taxes lost due to smoking" indicate the loss due to earlier disability/retirement, and "Pension costs" indicate the pensions paid by the state and pension companies. The value of one quality adjusted life year lost was estimated to be $0.74 \times € 30,000 = € 22,200$.^{10,25}


Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.



er review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).



er review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	Done	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2 pp. 3,4	Explain the scientific background and rationale for the investigation being reported
Objectives	3 p. 4	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4 p. 4	Present key elements of study design early in the paper
Setting	5 p. 4	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6 pp. 4,5	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7 pp. 4,5	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8* pp.4,5	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9 Not done	Describe any efforts to address potential sources of bias
Study size	10 p. 4	Explain how the study size was arrived at
Quantitative variables	11 pp. 4,5	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12 p. 5	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed No missing data
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses


Continued on next page

Results		
Participants	13* p. 4	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage No drop-outs or missing data (c) Consider use of a flow diagram
Descriptive data	14* Done	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Table 2 (b) Indicate number of participants with missing data for each variable of interest No missing data (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) p. 4
Outcome data	15* Done	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures Tables 1 and 2
Main results	16 Done	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses No such analyses
Discussion		
Key results	18 pp. 6, 7	Summarise key results with reference to study objectives
Limitations	19 pp. 8, 9	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20 p. 9	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21 p. 9	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22 p. 11	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Figure 1. Average annual health care costs per living individual, in Euros, as a function of age.




131x90mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Average annual health care costs among all individuals in Euros (including deceased persons).



120x90mm (300 x 300 DPI)

ew only